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ABSTRACT

THE COURSE OF AXIS I AND AXIS II DISORDERS IN CLINICAL HIGH RISK
(CHR) ADOLESENTS
Christy DaBreo-Otero
The detrimental impact of psychosis on individuals and society has sparked
interest in early detection and intervention strategies to improve outcomes for those who
are high-risk for developing psychosis. This study used data collected by the Recognition
and Prevention (RAP) program to explore the progression of Axis I and Axis II disorders,
clinical and functional characteristics, and predictors of conversion in a Clinical High
Risk (CHR) sample. Using the RAP Program’s classification system, participants were
assigned to the following subgroups based on symptom presentation: Clinical High Risk
Positive (CHR+) which is defined by the presence of attenuated positive symptoms and
Clinical High Risk Negative (CHR-) which requires the presence of attenuated negative
symptoms.
Participants consisted of 156 subjects (110 males and 46 females) who
participated in the RAP Program during Phase I (2000-2006) and were separated into the
high-risk groups: CHR+ and CHR-. These results indicated that Axis I disorders (mood,
anxiety, substance use, and attention-deficit and disruptive behavior disorders) presented
similarly at baseline in the CHR subgroups, however there were significant differences in
the prevalence rates of paranoid personality disorder, borderline personality disorder, and
schizoid personality disorder. In exploring the relationships between psychiatric

disorders, attenuated symptoms, and functioning, it was found that lower levels of role
functioning were associated with mood disorders for CHR- participants. Additionally,
social functioning and attenuated negative symptoms were found to have an impact on
Cluster A personality presentation in both CHR subgroups. This study also explored the
progression of psychiatric disorders, and results demonstrated that mood, anxiety,
attention-deficit and disruptive behavior disorders, and personality disorders were
persistent and recurrent from baseline to follow-up in both subgroups. Additionally, in
examining predictors of conversion, positive symptoms were found to be the strongest
predictor of conversion to psychosis and mood disorders were found to be a significant
predictor of non-conversion.
The results from this study convey that CHR adolescents present with a
constellation of diagnoses and symptoms. The findings suggest that it may be beneficial
to continue to screen individuals diagnostically to develop specific intervention strategies
based on how participants are assigned to high-risk groups.
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Chapter 1: Introduction
This dissertation contributes to an area of research that focuses on individuals
who are clinical high risk (CHR) for developing psychosis. Specifically, this study will
use data collected by the Recognition and Prevention (RAP) Program, a longstanding
CHR Program in New York, to examine the baseline prevalence rates of co-occurring
psychiatric disorders in a high-risk population and clinical and functional characteristics.
Additionally, this study will explore which baseline characteristics predict conversion to
psychosis and assess the long-term stability of psychiatric disorders in individuals who
are at CHR in this cohort. The outcomes of these analyses may have important
implications for prevention and/or treatment for high-risk populations.
Rationale and Significance
There has been emerging interest in the early detection and prevention of
psychosis, in particular schizophrenia. There is considerable research demonstrating the
debilitating effects of psychosis and the detrimental impact it has on an individual’s
quality of life. Individuals suffering from psychosis often experience cognitive
difficulties, difficulties in maintaining interpersonal relationships, and role functioning
problems such as academic and employment difficulties (Barch & Sheffield, 2014; de
Waal, Dixon, & Humensky, 2018; Karambelas et al., 2018; McCann, Lubman, & Clark,
2011; Redmond, Larkin, & Harrop, 2010; Schaefer, Giangrande, Weinberger &
Dickinson, 2013; Sheffield, Karcher, & Barch, 2018; Tolman & Kurtz, 2012).
Unfortunately, this population is also susceptible to high mortality rates due to physical
health problems and high rates of suicide (Castagnini & Bertelsen, 2011; Henderson,et
al., 2015; Pompili et al., 2011; Suvisaari, et al., 2010). Due to these poor outcomes, over
1

the past twenty years there has been interest in prevention and developing criteria to
identify individuals in this pre-psychotic phase of illness., as this may provide a window
of opportunity for intervention. Terms such as “at risk”, “ high-risk”, “clinical high risk”,
“ultra high risk”, and “prodromal” are used to categorize individuals in this phase in the
ever growing literature on the subject.
Extensive research on the potential negative long-term outcomes of psychosis has
propelled the prevention movement to gain momentum, calling for early intervention to
begin as soon as possible, before psychosis becomes particularly disruptive to social,
academic, and occupational functioning (McGorry, Killackey, & Yung, 2008). By
targeting individuals who are at-risk for developing psychosis, we may be better able to
identify factors that predict conversion to psychosis, which could in turn help to more
readily inform early intervention strategies. Interest in early intervention research has led
to the development of reliable and valid instruments which are used to identify
individuals who are high-risk for developing psychosis. Many high-risk studies over the
last several decades provided clues about predictors of conversion, and showed rates of
conversion as high as 50%, with more recent rates between 17% and 35% (Fusar-Poli et
al., 2012; Michel, et al., 2018; Miller et al., 2002; Yung et al., 2005). The decline in
conversion rates may be attributed to false-positives, tailored intervention models, the
promotion of early intervention programs, and the development of assessment measures
(Yung and McGorry, 1996; Yung et al., 2007).
Many studies also suggest that there is a high co-occurrence of nonpsychotic
disorders in individuals at-risk for psychosis. In fact, most help-seeking individuals cite
nonpsychotic symptoms such as mood, anxiety, substance use, or behavioral problems as
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their presenting concern which may overshadow high-risk symptoms (Falkenberg, et al.,
2015; McAusland et al., 2017; Woods et al., 2009). Given the cooccurrence of other
psychiatric disorders in this population and declining transition rates to psychotic
disorders, it is important to investigate how co-occurring disorders impact the outcomes
of those who do and do not develop psychosis.
Statement of Purpose
Using longitudinal data collected from the Recognition & Prevention (RAP)
Program at Zucker Hillside Hospital, this study will assess the development of high-risk
symptoms and potential associations with psychiatric disorders. Furthermore, to better
understand the impact of psychiatric disorders on prodromal symptomatology and risk for
conversion to psychosis, this study will assess how these disorders evolve in different
stages of the prodrome.

3

Chapter 2: Literature Review
Rationale for Identifying Risk for Psychosis
Psychotic disorders are mental illnesses which are characterized by impairment in
perception, emotional experiences, and behavior. Psychotic disorders affect about 3% of
the population, with the onset typically occurring between the ages of 15 and 25.
Psychotic disorders include schizophrenia (0.3-0.7%), schizophreniform disorder,
schizoaffective disorder (0.3%), delusional disorder (0.2%), brief psychotic disorder, and
other schizophrenia spectrum disorder. Individuals also can meet criteria for psychosis if
diagnosed with a bipolar or depressive disorder with psychotic features or with a
diagnosis of substance or medication induced psychosis (American Psychiatric
Association, 2013).
Individuals who meet criteria for psychosis vary in their presentation due to their
own unique combination of symptoms and experiences. Symptoms associated with
schizophrenia are classified into two categories: positive symptoms and negative
symptoms. Positive symptoms include hallucinations which are perception-like
experiences that occur without an external stimulus and delusions which are fixed beliefs
that are held despite evidence that suggests these beliefs may not be true. These
symptoms are separate from negative symptoms, which include diminished emotional
expression, avolition, and anhedonia which could lead to difficulties with attention,
concentration, social and occupational functioning (American Psychiatric Association,
2000; Marder & Galderisi, 2017; Tsuang, Glatt, & Faraone, 2011).
It has been well documented that psychiatric comorbidities are common among
people with schizophrenia. According to Buckley et al. (2009), anxiety symptoms are
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common throughout the course of schizophrenia, with estimated prevalence rates of 15%
for panic disorder, 29% for posttraumatic stress disorder, and 23% for obsessive
compulsive disorder. It is also estimated that comorbid depression occurs in 50% of those
affected by the illness. These nonpsychotic disorders accompanying schizophrenia make
it challenging to form an accurate clinical picture of individuals who are affected.
Moreover, it is unclear as to what extent these symptoms solely reflect psychological
distress or are indeed unique features of a psychotic illness (Buckley et al., 2009).
There is substantial research to support that attention-deficit and disruptive
behavior disorders and schizophrenia share similar symptomatology (Brodeur, Kiang, &
Christensen, 2016; Donev et al., 2011; Niarchou et al., 2018; Oie & Rund, 1999;
Salomon et al., 2011; Starc et al., 2017). The overlap in symptoms includes impulsivity,
inattention, impairment in working memory, disorganized behavior, and emotion
dysregulation, which can impact overall functioning and prognosis over time (Bae et al.,
2010; Jobe & Harrow, 2010; Prouteau et al., 2015). Specifically, for ADHD, adolescents
who carry this diagnosis are 4.3 times more likely to develop schizophrenia in the future
in comparison to healthy controls (Dalsgaard et al., 2014). Additionally, externalizing
behaviors such as conduct disorder are linked to the development of schizophrenia later
in life (Rubino et al.,2009).
Individuals with schizophrenia often present with substance use and rates indicate
that these individuals may engage in substance use at higher rates compared to the
general population. Substances that are often reported are alcohol, nicotine, and cannabis,
and opioids. (Khokhar et al., 2018; Winklbaur et al., 2006). As explained by Awad and
Voruganti (2008), substance use is particularly dominant among individuals suffering
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from schizophrenia, with approximately 50% meeting diagnostic criteria for a substance
use disorder at some point in their lives. In addition, up to 25% of individuals with
schizophrenia may be actively engaged in substance use at any given time during their
illness (Awad, &Voruganti, 2012; Buckley & Meyer, 2009). For this population,
increased substance use is associated with increased hospitalizations and low treatment
compliance.
The symptoms and impairments associated with schizophrenia appear to be longstanding with periods of fluctuation in severity occurring over time (Hersen & Beidel,
2012). The course of schizophrenia is variable with symptoms wavering in severity and
intensity (Jones, Hacker, Cormac, Meaden, & Irving, 2012; Perälä et al., 2007). As
symptoms become more severe, it may be increasingly more difficult for people to stay in
touch with reality, maintain relationships, and manage tasks required for daily living
(Awad & Voruganti, 2012). According to Awad & Voruganti (2008) the early onset and
chronic nature of schizophrenia often results in direct and indirect costs to the
individuals affected and their family members and caregivers. Individuals affected are
likely to encounter medical costs for hospital stays, out-patient care, rehabilitation,
assisted living, and other health professional services. Other difficulties include loss of
productivity, leading to unemployment. These indirect costs resulting from not being able
to work can place a toll on these individuals, their families, and society. Caregivers report
experiencing guilt, worry, shame, and feeling despair for themselves and their affected
family member (Barker, Lavender, & Morant, 2001). Individuals with schizophrenia may
also experience emotional suffering, social isolation, emotional distress, depression, and
even premature death (Lindström, Eberhard, Neovius, & Levander, 2007). Because of
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these substantial costs, there has been emerging interest in early detection and
intervention strategies to alleviate, or if possible, prevent these outcomes.
Treatment options for schizophrenia include psychiatric medication and
psychotherapy. Antipsychotic medications such as haloperidol, risperidone, and
olanzapine have proven to be effective in combination with other therapeutic
interventions such as such as CBT for psychosis (Dold et al., 2015; Lecomte 2015;
Olivares, Pinal, & Cinos, 2011). Individual therapy, family therapy, and social skills
training have also proven to be beneficial (Granholm, Holden, & McQuaid, 2014;
Haddad, Brain & Scott, 2014). Although these forms of treatment continue to be helpful
and beneficial for the positive symptoms of schizophrenia, oftentimes, patients are left
with negative symptoms which account for severe difficulties in functioning and quality
of life in addition to the costs of treatment such as hospitalization and medication (Patel,
Cherian, Gohil, & Atkinson, 2014). Even with optimal treatment, persons with
schizophrenia often continue to experience substantial impairment throughout much of
their lives with many struggling with caring for themselves and others (Ofir et al., 2017).
In addition to the challenges listed above, individuals affected by psychosis are
also highly stigmatized. The diagnostic label evokes perceptions that individuals with
psychosis are dangerous, violent, and unpredictable (Corrigan & Kleinlein, 2005;
Durand-Zaleski, Scott, Rouillon, & Leboyer, 2012). Furthermore, experiences of
internalization of stigma may occur and can lead to emotional distress in the form of
depression and anxiety which may have a detrimental impact on recovery, contribute to
increased shame, and lower treatment adherence (Birchwood et al., 2007; Rusch et al.,
2014). In conclusion, the debilitating effects of psychosis have ushered further
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exploration of the period before the onset of full-blown psychosis to mitigate adverse
long-term impact, improve symptoms, and boost functional outcomes.
The Psychosis Prodrome: A Historical Perspective
The onset of psychosis varies in length and can be characterized by nonspecific
changes in thoughts, feelings, behaviors, and functioning. An individual who develops a
psychotic disorder typically displays symptoms 1-2 years prior to the first psychotic
break. The time period when symptoms preceding the onset of psychosis are developing
is referred to as the prodromal period, and typically occurs during late adolescence or
early adulthood (Häfner et al., 2003). As explained by Salokangas and McGlashan (2008)
“the prodrome for psychosis is a retrospective concept referring mostly to the period from
the first noticeable symptoms of unusual experiences to the first prominent psychotic
symptoms” (p.95). The prodromal period can last several weeks, months or years while
co-occurring with other disorders and leading to possible functional decline (Larson,
Walker & Compton, 2010; Woods et al., 2010).
Presentation of symptoms include attenuated positive symptoms which are not
severe enough to meet criteria for psychosis and precede full-blown psychosis.
Prodromal symptoms are deviations in thinking patterns, behavior, and affect. Individuals
in this phase may present with odd beliefs or unusual behaviors. They may have speech
that appears vague, overly concrete, or disorganized. Others may note they have
difficulty holding a conversation. Typically, attention problems, depression, anxiety,
social difficulties, disorganization, and sleep disturbances emerge first, and then more
specific attenuated psychotic experiences emerge later. Other common concerns include
difficulties with memory and low motivation. Individuals may describe experiences
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where they feel like their thoughts are disappearing, blocked, or coming very rapidly.
There may be reports that others may know their thoughts possibly accompanied by
increased suspiciousness. However, these thoughts are not at the intensity of paranoid
delusions and the disorganized communication does not meet full criteria for a formal
thought disorder (Goulding et al., 2013). Individuals may report experiences of others
watching them, trying to harm them, or feeling fearful without any specific trigger.
Individuals may also report losing interest in activities, becoming socially withdrawn,
and displaying less affective expression. Although reports of perceptual experiences and
ideations may arise, they do not meet the severity of delusions and hallucinations
(Goulding et al., 2013). Family members, teachers, and others who interact more closely
with the individual are likely to recognize changes in behavior. As these symptoms
occur, individuals are likely to feel confused, frightened, and even doubt their
experiences. These symptoms may present gradually over several months or years before
a full onset of psychosis (Larson, Walker, Compton, 2010; Perkins, 2004). These changes
may also impact a person’s ability to remain focused in school, maintain stable
employment and relationships, causing distress over time.
Individuals in the prodromal phase present with psychotic-like experiences which
are different from full-blown psychosis in that the person questions or doubts their
experiences. For example, a person may think that someone can read their mind and may
be uncertain whether or not this experience is real or imaginary. As explained by Kline et
al. (2012), the difference between psychotic and psychotic-like experiences lies in
expression of doubt, conviction of reality of the experience. Generally, if these symptoms
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persist, they may evolve into psychosis but not all psychotic-like experiences are
predictive of full-blown psychosis.
To be in the prodromal phase implies that there will be a progression to psychosis.
Much of the research on the prodrome has relied on retroactive studies, suggesting that
conversion to psychosis is inevitable. However, there is ample research to suggest that
the majority of help-seeking individuals do not go on to develop psychosis (Cannon et al.,
2008; Cornblatt et al., 2003; Yung et al., 2004). Also, prodromal symptomatology is not
just related to psychotic symptoms and can be non-specific, further highlighting that the
presence of prodromal symptoms does not subsequently indicate conversion to psychosis.
To reconcile this discrepancy, there has been a shift in the research field to replace the
term prodrome with other terminology such as at-risk, high-risk, clinical high risk, and
ultra high risk to accurately capture the vulnerability rather than imminency of psychosis
(Fusar-Poli et al., 2013).
Conceptualizing the High-Risk Stage
In the last couple decades, there has been a considerable shift to understand the
complexity and course of psychosis which has led to several advancements such as
reliable and structured instruments to identify individuals at-risk, longitudinal studies to
identify mechanisms and functional outcomes, and therapeutic and pharmacological
interventions to delay or prevent onset of psychosis (Woodberry, Shapiro, Bryant, &
Seidman, 2016). The diversity, complexity, and variedness of non-specific features of the
prodrome coupled with the long-term impact of psychosis on cognitive, emotional, and
social development have led to the development of several models to conceptualize the
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high-risk state. These models provide criteria to assess symptoms to more accurately
identify individuals at-risk and then to provide appropriate treatment.
Basic Symptoms. Early attempts to describe high risk symptoms were first made
by Huber and Gross who identified basic symptoms as early manifestations of psychosis.
These symptoms are essentially subtle subjective experiences of disturbance marked by
changes in cognition, affect, and perception (Huber & Gross, 1989). This approach is
based on retrospective studies on the prodrome and has gained widespread recognition in
Germany and other parts of Europe as of the late 1990s. As explained by Larson, Walker,
Compton (2010) basic symptoms are the first symptoms to develop and are “subjective
experiences of thought, language perception, motor disturbances; impaired bodily
sensations; impaired tolerance to stress; disorders of emotion, thought, energy,
concentration and memory; and, disturbances in social functioning.” (p. 4).
Basic symptoms manifest as subjective experiences and are rarely outwardly
observed by others. This approach proposes that there are levels of progression of
symptoms with subtle non-specific cognitive disturbances emerging first, then thought
interference, speech difficulties, automatic skills deficits appearing later, and then lastly
frank psychosis (Schultze-Lutter et al., 2010). These symptoms can be further assessed
using the subscales: cognitive-perceptive basic symptoms (COPER) and cognitive
disturbances scale (COGDIS). COPER requires the presence of at least one of ten basic
symptoms within the last three months and COGDIS requires the presence of at least two
of nine basic symptoms within the last three months (Schultze-Lutter & Theodoridou,
2017).While this approach is not widely recognized in the United States, it has
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influenced the development of other high-risk models which will be further expanded on
below.
Ultra High Risk. The basic symptom approach helped to lay the groundwork for
high-risk research and also revealed some shortcomings in the current methodological
approaches at the time. For instance, many subjects in research studies were incorrectly
labeled as at risk for psychosis but did not actually develop psychosis (Falloon, 1992;
Yung & Nelson, 2013). Previous studies also further highlighted the challenges of
prospectively identifying individuals in the prodromal state due to nonspecific nature of
prodromal symptoms. The ultra high risk (UHR) approach arose out of the need to
minimize the concerns surrounding the false-positives and to widen the risk criteria to
identify high-risk groups.
The UHR approach considers the age of the individual acknowledging that
psychotic symptoms tend to appear in adolescence or early adulthood, specificity of
symptoms, and genetic and clinical risk factors in identifying those at risk. Additionally,
the name ultra high risk, also distinguishes help-seeking individuals from other high-risk
groups such as those who may have a genetic risk. As explained by Yung & Nelson
(2013), to meet UHR criteria, the individual must be between the ages of 15 and 25 years
old, experience a decrease in functioning for at least one month or sustained low
functioning during the past year, and meet criteria for one of the following groups:
attenuated positive symptom syndrome (APS), brief limited intermittent psychotic
syndrome (BLIPS), and trait vulnerability group. To meet criteria for APS, there must be
the presence of attenuated psychotic symptoms within the past year. Individuals must
endorse at least one of the following symptoms such as odd beliefs or magical thinking,
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ideas of reference, perceptual disturbance, paranoid ideation, odd behavior or appearance,
odd thinking and speech at the high-risk level. To meet criteria for BLIPS, individuals
must endorse the same symptoms, but at a psychotic level of severity for a brief duration.
These transient symptoms should last for less than one week and resolve spontaneously
within a year. To meet criteria for trait vulnerability, an individual must present with a
genetic vulnerability to a psychotic disorder such as having a family history of a
psychotic disorder in a first-degree relative or the individual meeting diagnosis for
schizotypal personality disorder.
These ultra high risk categories were used to create the Structured Interview for
Prodromal Syndromes (SIPS) along with its companion Scale of Prodromal Symptoms
(SOPS) which were developed by McGlashan and colleagues at Yale University and are
widely used in the United States. According to McGlashan, Walsh and Woods (2010),
the SIPS and SOPS were developed to identify the presence/absence of one or more of
the psychosis risk-states; to measure the severity of risk symptoms cross-sectionally and
longitudinally; and to define the presence/absence of psychosis. The SIPS also consists of
the Criteria of Prodromal Syndromes (COPS) which provides operationalized definitions
of the clinical high risk (CHR) syndromes: attenuated positive symptom syndrome
(APS), brief intermittent psychotic syndrome (BIPS), and genetic risk and deterioration
syndrome (GRD).
Clinical High Risk. The Clinical High Risk (CHR) approach has incorporated
ultra high risk criteria since its inception and also provides the basis for this current study.
The Clinical High Risk approach developed by Cornblatt and colleagues at the
Recognition and Prevention (RAP) Program proposes that high-risk symptoms progress
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along a continuum and uses the SIPS and SOPS as the basis for this classification
(Cornblatt et al., 2003).
Compared to previous pioneers such as McGorry, Yung and colleagues, the RAP
Program is unique as it incorporates a neurodevelopmental perspective to track the
longitudinal progression of high-risk symptoms over time. As explained by Cornblatt
(2002), the neurodevelopmental model of schizophrenia proposes that psychosis is the
result of structural, functional, and biochemical abnormalities occurring during prenatal
development. These abnormalities lead to a biological vulnerability which presents as
cognitive deficits, affective symptoms, social isolation, and school failure. Subsequently,
genetic, biological, or environmental triggers may then cause positive symptoms to
develop which may lead to full-blown psychosis. Cornblatt et al (2015) explains that
there are three stages: The first stage or pre-illness phase is marked by neurocognitive
deficits, followed by the prodromal phase where behavioral changes are observed, and
then the final stage of full-blown psychosis (See Figure 1).
Early studies focused on the prodrome as a single entity, leaving very little room
for the possibility of multiple pre-psychotic phases. The RAP program’s classification
system shifted the way the prodromal phase is viewed by focusing on developmental
stages. The RAP program’s classification system is grounded in the staging theoretical
framework which has been widely used in medicine but only recently applied to studying
the psychosis risk syndrome (McGorry et al., 2007). Using the SIPS, the RAP Program
developed criteria to classify individuals at high-risk based on the presence of positive
and negative symptoms (Cornblatt et al., 2003). According to Cornblatt and colleagues,
there is an early period and late period in the prodromal phase of illness. In the early
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prodromal phase, attenuated negative symptoms and affective symptoms begin to
emerge, affecting an individual’s functioning. The late prodromal phase is defined by the
development of attenuated positive symptoms. For some individuals, the symptoms then
progress to psychosis.
This developmental model proposed by Cornblatt and colleagues provides a
number of different entry points into the prodrome and is categorized by stages. During
the first stage referred to as Clinical High Risk Negative (CHR-), individuals may present
with nonspecific, attenuated negative symptoms such as increased social isolation, school
failure, decreased expression of emotions, and rigid thinking. For this stage, individuals
must score at least a 3 on the SOPS on the negative symptom scale, signifying moderate
to severe intensity. This stage is then followed by the Clinical High Risk Positive (CHR
+) stage where individuals present with attenuated positive symptoms with a SOPS score
between 3 and 5. Symptoms reported may include disorganized speech, unusual thought
content, cognitive changes, and perceptual abnormalities. The final category which is
schizophrenia like psychosis (SLP), requires that an individual present with at least one
psychotic level symptom (6 on the SOPS) but they do not meet full criteria for
schizophrenia (Lencz, et al., 2004). For the purposes of this study, we will be focusing
only on the CHR+ and the CHR- subgroups (See Figure 2).
This model allows one to track the progression of the illness over time, which also
helps to inform stage-specific interventions. This also leaves space to further develop
criteria to identify early risk factors for high-risk individuals. Research regarding
appropriate interventions for high-risk individuals is crucial given the indeterminate
nature of the high-risk state, the fact that the majority of high-risk individuals will never
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develop psychosis, and the issue that many medications, namely antipsychotic
medications, carry serious side effect risks (Corcoran, Malaspina, & Hercher, 2005). The
choice of intervention in the prodrome is further complicated by the presence of frequent
psychiatric comorbidities in high-risk individuals.
Validity of High-Risk Syndromes
In studies detecting psychosis risk, high risk groups that are often referenced are
ultra high risk (UHR) and clinical high risk (CHR). UHR is mostly used in Europe and
Australia and is assessed by using the CAARMS, whereas, CHR is frequently used in
North America and is assessed by the SIPS. Despite, some differences in the types of
instruments used to assess risk, CHR and UHR are fairly similar in their categorization of
high-risk individuals (Correll, Hauser, Auther, & Cornblatt, 2010; Miller et al., 2003).
Both the SIPS/SOPS and CAARMS assess positive symptoms, negative symptoms,
disorganization symptoms, and general symptoms (Correll, Hauser, Auther, & Cornblatt,
2010).
Several studies have been conducted to evaluate the diagnostic validity of the
prodromal risk syndromes described above. The SIPS was first tested for validity in
2000, with the results showing that 46% of the participants who met at-risk criteria
developed schizophrenic psychosis after 6 months, and 54% at 12 months (Miller et al.,
2003). In a more recent study, the validity of the SIPS was assessed using a pooled
sample from 8 academic research centers in North America: Emory University, Harvard
University, University of California Los Angeles, University of North Carolina,
University of California San Diego, University of Toronto, Yale University, and Zucker
Hillside Hospital who are part of the North American Prodrome Longitudinal Study
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(NAPLS) consortium. Results demonstrated that, of the 291 participants who completed
follow-up, 82 converted to psychosis over 30 months. The cumulative prevalence rate of
conversion to psychosis was 35.3% over this time period (Cannon et al., 2008). In
another NAPLS study evaluating predictive validity, prodromal risk participants were
compared to several groups (e.g. normal controls, help-seeking controls, familial risk
subjects, and subjects with schizotypal personality disorder) on different domains such as
functioning, follow-up outcome, and symptom profile (Woods et al., 2009). Overall, the
results showed that the prodromal risk participants were more symptomatic compared to
the other groups and were more likely to convert to psychosis over a 2-year period. These
findings support the diagnostic validity of this risk syndrome for psychosis (Woods et al.,
2009).
The use of valid and reliable assessment tools has been a critical step towards
early identification and intervention strategies for high-risk individuals. The advancement
in assessment tools have led the way to improving recruitment strategies, identifying
symptoms, and increasing our understanding of the high-risk clinical presentation.
Early Intervention Programs
Early intervention research for psychotic disorders is viewed as having the
potential to produce better outcomes in individuals vulnerable to developing psychosis
and to reduce some of the clinical and economic burdens associated with the illness
(Fusar-Poli et al., 2013; Stafford, Jackson, Mayo-Wilson, Morrison & Kendall, 2013).
This line of logic is deeply rooted in preventative medicine research.
Mrazek and Haggerty (1994) described some of the challenges in the
classification system used to categorize prevention for physical illnesses. They pointed
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out that the previous categorization primary, secondary, and tertiary prevention is
ambiguous when applied to the prevention of progression of mental illness as it is unclear
how prevention measures are implemented when there is no clinically diagnosable
disorder. These researchers reorganized the classification system into universal
prevention, selective prevention, and indicated prevention. Indicated prevention, which
targets high risk individuals who present with minimal but detectable symptoms is of
particular importance in early intervention research as it targets individuals who are of
especially high risk of developing serious mental disorders such as psychosis (Mrazek &
Haggerty, 1994, p.22-24).
Within the last 30 years there has been emerging interest in indicated prevention
which has paved the way for high-risk research and treatment by helping researchers and
clinicians explore methods to prevent or postpone the onset of psychosis and develop
treatment options to address presenting symptoms. Ideally, indicated prevention may
provide potential benefits where help-seeking individuals either return to their previous
level of functioning or maintain their current level of functioning (Correll, Hauser,
Auther, & Cornblatt, 2010; Fusar-Poli et al., 2016). The field of prevention research is
exciting as it sheds light on the development and course of psychotic illness. It also
involves identifying individuals who are in the pre-psychotic phase of illness, meaning
that they are presenting with prodromal or high-risk symptoms.
Early intervention programs consist of a multidisciplinary team of mental health
professionals who provide therapeutic and psychopharmacological interventions that are
tailored to the needs of help-seeking individuals (McGorry, Killackey, & Yung, 2007).
High-risk research and treatment programs have proliferated around the world and been
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largely successful and informative in increasing our understanding of high-risk states.
Australia and some parts of Germany were the front runners for early intervention
programs, but now there are many programs that can be found in the United States,
Canada, and Asia. These programs vary in their methodological approaches, assessments,
and duration while offering support to help-seeking individuals and their
families/caregivers (McGorry, Killackey, & Yung, 2008).
Effective treatments have been identified through these early intervention
treatment programs. For instance, cognitive therapy, which has been shown to be
effective in mitigating effects of psychosis may also reduce the severity of psychotic
symptoms in young individuals when utilized as a preventative intervention (Morrison et
al., 2012). Comparatively, in another study conducted by McFarlane et al (2015), a
therapeutic intervention called Family-aided Assertive Community Treatment (FACT)
was proven to be effective in improving negative, disorganized, and general symptoms.
Other studies have investigated potential beneficial effects of omega-3 fatty acids on
preventing onset of psychosis (Amminger, et al., 2015; Mosshaeb, 2012). Additionally, a
meta-analysis assessing the efficacy of early intervention treatment options revealed that
omega-3 and CBT demonstrated good effect in reducing transition rates in high- risk
participants. Antipsychotic medications were mostly found to be somewhat effective in
delaying conversion to psychosis, but are associated with side effects and high attrition
rates. (van der Gaag et al., 2013).
It is also noteworthy that in North America, many sites have collaborated to form
the aforementioned NAPLS which is a consortium of eight early intervention programs in
North America. Sites participating in the NAPLS consortium contributed their

19

preexisting data sets to form a larger sample of CHR individuals with more power to
further assess outcomes. These early intervention programs have largely contributed to
high-risk research by exploring treatment options, neuropsychological profiles, and risk
algorithms for CHR individuals. Treatment outcomes from recent NAPLS studies have
revealed that CHR participants are more likely to report experiencing stressful life events
and to experience daily hassles (Trotman et al., 2014) and also report higher baseline
cortisol levels compared to healthy controls (Walker et al., 2013). Based on several
NAPLS studies, there are observed impairments in functioning for CHR individuals
(Fusar-Poli et al., 2013; Piskulic et al., 2016; Seidman et al., 2010; Seidman et al., 2016;
Velthorst, 2019). Cornblatt et al. (2012) found that social and role functioning remained
relatively stable in CHR subjects who converted to psychosis. In contrast, role
functioning improved over time in nonconverters. Additionally, using multivariate
models, NAPLS studies have identified biomarkers (e.g., neuroimaging and
electrophysiology) and predictive algorithms to more accurately identify predictors for
conversion (Cannon et al., 2016). This consortium went on to collect prospective genetic
samples and conducted further research on the biological underpinnings of psychosis.
The Recognition and Prevention (RAP) Program. A program founded by
Barbara Cornblatt in 1998 and is one of the first early intervention programs in North
America to investigate and treat individuals who are high risk for psychosis. Since its
inception, the program has contributed to research on the progression of symptoms in
CHR individuals while offering educational resources and treatment options for young
adults and their families.
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Research studies of the RAP Program have focused on identifying vulnerability
markers that may be unique to CHR individuals. Studies from the RAP Program have
specifically concentrated on social functioning, role functioning, and overall
neurocognitive functioning using a variety of testing batteries and assessments. RAP
studies consistently demonstrate that CHR individuals report significant impairments in
social and role functioning suggesting that these impairments may serve as potential risk
factors (Carrión et al., 2011, 2013; Cornblatt et al., 2012; Olvet, Carrión, Auther, &
Cornblatt, 2015). In a study conducted by Carrión et al. (2018) comparing baseline
neurocognitive performance across different groups (healthy controls, CHR individuals,
and individuals in the early first- episode phase of psychosis), it was found that verbal
learning impairment was most predictive of conversion to psychosis. This finding is
noteworthy, implying that verbal learning may be a vulnerability marker and could
inform specific interventions for high-risk individuals. Additionally, CHR individuals
who did convert to psychosis presented with similar functioning compared to those
subjects in the early first-episode phase of psychosis, supporting the likelihood of
functioning declining during the progression of psychosis (rather than as a result of
psychosis). In another study comparing CHR subjects to healthy controls, CHR subjects
highlighted that auditory mismatch negativity (MMN) may impact baseline functioning
and is negatively correlated with reading ability, social and role functioning (Carrión et
al., 2015). Other studies have found that longer duration of negative symptoms to be
associated with poorer social functioning, severity of attenuated positive symptoms to be
a predictor of conversion to psychosis, and disorganized symptoms, impaired social
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functioning, and low processing speeds to predict poor social functioning (Carrión et al.,
2016; Carrión et al.,2013).
Using the framework of the RAP model, this study aims to further explore the
progression of symptoms in CHR subjects and how clinical profiles may evolve during
different stages of the model.
Psychiatric Comorbidities in High-Risk Populations
As mentioned previously, the psychiatric comorbidities with schizophrenia have
been well-documented. Given the cooccurrence of nonpsychotic disorders with high- risk
symptoms, it is important to examine the prevalence rates, progression of these disorders,
and functional outcomes in high-risk youth. It is essential to accurately identify comorbid
disorders as this has implications for early intervention and treatment options. This study
will assess the course of Axis I and Axis II disorders using DSM-IV criteria, which was
in use at the time of data collection.
Prevalence of Axis I Disorders
Mood and Anxiety Disorders. Similar to findings in schizophrenia research,
affective and anxiety disorders are frequently observed in the high-risk population and
may prompt help-seeking individuals to seek treatment.
An earlier retrospective study of the schizophrenia prodrome conducted by
Hafner and colleagues (1998), identified depression as the most frequently endorsed
symptom preceding the onset of psychosis. Hafner and colleagues suggested that
depression might actually be an expression of the development of psychotic illness
process. Later studies assessing the progression of depressive symptoms confirmed that
depression may impact psychosis onset (Yung et al., 2007).
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A recent meta-analysis of prospective high-risk studies found that about 73% of
at-risk participants had at least one comorbid Axis I diagnosis, with the most common
being depressive and anxiety disorders (Fusar-Poli et al., 2014). Research findings show
that non-bipolar mood disorders appear to be prevalent in the high-risk population. FusarPoli et al. (2014) found that 41% of high-risk subjects met criteria for a depressive
disorder. In a NAPLS study consisting of 377 participants, 55% met criteria for a
depressive disorder (Woods et al., 2009). In another study assessing transition to
psychosis in a CHR sample, it was observed that 34% of participants met criteria for a
depressive disorder (Salokangas, et al., 2012). Among several high-risk studies, major
depressive disorder appears to be the predominant mood diagnosis in this population
(Kline et al., 2018; Lin et al., 2015; Meyer et al., 2005; Rosen et al., 2005; Salokangas, et
al., 2012). Depressed mood appears to be associated with poor role and social functioning
(Fulford et al., 2013). In another study assessing the prevalence of depressive disorders,
CHR participants with current or past depression also demonstrated more impairments in
functioning and more severe negative symptoms (Kline et al., 2018).
Anxiety is also commonly observed in the CHR population (Addington et al.,
2011; Fusar-Poli et al., 2014; Woods et al., 2009). In one study consisting of a CHR
sample of 765 subjects, 51% met criteria for an anxiety disorder with social phobia being
the most common. (McAusland et al., 2017). Other studies have replicated similar
findings of social phobia being the most prevalent of all anxiety disorders among highrisk individuals (Hui et al., 2013; Meyer et al., 2005; Svirskis et al., 2005).
Several longitudinal studies have been conducted to assess obsessive compulsive
disorder (OCD) in high-risk individuals. One study revealed sizable prevalence rates of
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20% in high-risk youth, but after 12 months none of the individuals diagnosed with OCD
converted to psychosis (Niendam et al., 2009). In contrast, in another study with a 12month follow-up, OCD symptoms at baseline predicted incident diagnosis of a psychotic
disorder at 12-month follow-up, showing that when attenuated psychotic symptoms are
accompanied by OCD symptoms, the risk for transition to psychosis increases (Van Dael
et al., 2011). Another study found that a diagnosis of incident OCD was associated with
higher rates of psychotic disorders at 7-year follow-up (Fontenelle, 2011). Fontenelle and
colleagues (2012) completed another study a year later where they assessed markers for
vulnerability to OCD with results demonstrating that participants who presented with
OCD and psychosis after the 7-year follow-up period displayed more severe levels of
depression and anxiety after conversion to psychosis.
Studies exploring the occurrence of comorbid Axis I disorders at baseline in at
risk participants found that common baseline diagnoses are major depressive disorder
(50%), anxiety disorders such as anxiety disorder not otherwise specified (NOS; 17%),
obsessive compulsive disorder (6.4%), and social phobia (17%; Fontenelle et al., 2011;
Meyer et al., 2005). In another study assessing the prevalence of depressive and anxiety
disorders in at-risk mental state (ARMS) participants, 40% of participants had a
comorbid depressive disorder, 8% had an anxiety disorder and 14% of participants had
both a depressive disorder and anxiety disorder (Fusar-Poli et al., 2014). These studies
confirm the common occurrence of anxiety and depressive disorders in high-risk
populations.
Attention Deficit and Disruptive Behavior Disorders. The well-documented
research on the overlap of symptoms associated with ADHD, disruptive behavioral
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disorders, and psychosis has also led to further research on how these symptoms manifest
before the onset of full-blown psychosis. Many individuals who are high-risk for
developing psychosis also present with ADHD diagnoses, externalizing behaviors, and
academic concerns (Karatekin, White, & Bingham, 2010). As explained by Simeonova,
Nguyen, and Walker (2014) “The general pattern of findings suggest that pre-psychotic
youth are more socially isolated, withdrawn, emotionally labile, anxious, and aggressive
than their healthy siblings and/or age-matched comparison subjects. They also have
higher levels of impaired attention, which remain stable and elevated from childhood to
adolescence, and are assumed to negatively affect social interactions leading to increased
stress related to social situations” (p.2). Some studies even suggest that ADHD may be a
vulnerability marker for psychosis but findings are inconsistent (Diwadkar, et al., 2011;
Keshavan et al., 2003).
There is evidence that inattention difficulties manifest for help-seeking
individuals who are high-risk (Francey et al., 2005; Pukrop et al., 2007; Simon et al.,
2007). Hurtig et al (2011) linked psychotic-like experiences to inattentive symptoms
(Hurtig et al., 2011). An earlier study conducted by Mazzoni et al (2009) demonstrated
that childhood-onset disorders were prevalent in young adults who met criteria for being
in the pre-psychotic phase. In this relatively small sample of 9 participants, diagnoses that
were endorsed included ADHD, elimination disorders, oppositional defiant disorder,
enuresis or encopresis, conduct disorder, separation anxiety, and transient tic disorder.
These findings support the viewpoint of a developmental perspective when exploring the
progression of symptoms in the high-risk state.
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Recent studies have further explored the connection between disruptive
behavioral disorders and identifying at risk youth. A more recent study conducted by
Simeonova et al.(2014), investigated whether or not parents’ report of social and
behavioral problems on the CBCL (Child Behavior Checklist) can be used to identify at
risk youth. Results indicated that the CBCL scales: Withdrawn/Depressed and Thought
Problems were the most useful in identifying at-risk youth which has implication for
developing future screening measures.
Substance Use. Research on the patterns and rates of substance usage in highrisk individuals varies which has led to interest in clarifying the relationship between
substance use and transition to psychosis. There are also differences in reports of rates of
substance abuse and dependence cooccurring within the pre-psychotic phase but the
consensus appears to be that cannabis, nicotine, and alcohol are the most commonly
reported used substances in CHR populations (Addington et al., 2014).
Varying rates of cannabis use and cannabis use disorders has been observed in
high-risk samples. Phillips et al., (2002) found that 37% of subjects reported using
cannabis at least once and 18% of subjects met criteria for cannabis dependence. Corocan
et al. (2008) observed that 41% of high-risk individuals endorsed cannabis use. Several
studies also compare cannabis use to use of other substances, citing varying rates among
high-risk participants. In a study conducted by Auther et al. (2015) baseline comparisons
revealed that alcohol use was reported in 45.3% of CHR youth and cannabis use rates
were 38.1%. Additionally, 85% of participants who reported cannabis use also reported
alcohol use, implying that individuals in this population are likely to use multiple
substances. In another study, at-risk participants reported increased tobacco, alcohol
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and cannabis use compared to controls and a noteworthy finding was that at-risk status
was significantly associated with higher alcohol use (Carney et al., 2017). Findings from
Buchy et al. (2014) cited that CHR participants endorsed more significant cannabis and
tobacco use and lower alcohol use over a one-year period. Also, in comparison to healthy
controls, CHR youth were more likely to report higher prevalence rates and frequencies
of cannabis use, the age of onset of use was younger, and they were more likely to use
cannabis alone. However, Russo et al. (2014) observed that healthy controls reported
higher cannabis use but lower alcohol use compared to high-risk individuals. It also
appears that use of more elicit substances is uncommon among CHR youth (Addington et
al., 2014; Buchy et al, 2015).
Prevalence of Axis II disorders
Research concerning personality pathology in at-risk participants is scarce but
there is evidence suggesting that schizotypal personality disorder (SPD) traits are similar
to the characteristic symptoms of schizophrenia, but are less severe (Ericson, Tuvblad,
Raine, Young-Wolff & Baker, 2011). The criteria for SPD can be separated into three
symptom dimensions (positive, negative, and disorganized) which are also consistent
with the diagnostic criteria for schizophrenia. Since, the criteria for SPD may be
attributed to a genetic loading or vulnerability to developing schizophrenia, it is actually
ideal for use in identifying individuals at-risk for psychosis. In fact, several strategies
have been used based on these criteria. Individuals are considered to meet at-risk
syndromes if they experience a recent onset of attenuated psychotic symptoms including
at least one of the following SPD symptoms: ideas of reference, odd beliefs, magical
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thinking, perceptual disturbance, odd thinking and speech, paranoid ideation, and odd
behavior or appearance.
High-risk symptoms and SPD shares some similar features but SPD is an
independent syndrome. The major distinguishing feature is that SPD is thought to be
longstanding and stable while high risk symptoms are thought to be progressing.
However, there are major gaps in the literature regarding the stability of this disorder.
There is a study conducted by Ericson and colleagues in 2011 which investigated the
genetic and environmental etiology of SPD traits in adolescent twins. These individuals
were identified as presenting with SPD traits and were assessed on two occasions
between the ages of 11 and 16 years old. They found genetic variance in the SPD traits
with moderate stability in SPD traits between early to middle adolescence. The
researchers suggested that future studies of schizotypal traits in individuals with
prodromal symptoms need to further explore other factors that may be operating (Ericson
et al., 2011)
While the research does suggest that the most common Axis II diagnosis is
schizotypal disorder for high-risk individuals with a prevalence rate of 21%, there is
some evidence that other personality disorders are present for this group as well. In a
study reporting on high-risk participants who did not convert to psychosis, Addington et
al. (2011) looked at Axis I and Axis II diagnoses and found that 29% of the sample had
consistent diagnoses at baseline and follow-up of avoidant, borderline, schizotypal, and
paranoid personality disorders and 14% had emerging diagnoses of avoidant, borderline,
and obsessive compulsive personality disorders at follow-up. These findings also
encourage further exploration of personality disorder development over time.
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Borderline personality disorder (BPD) has also observed in high-risk individuals.
Some of the symptoms associated with BPD are similar to attenuated positive symptoms
which are essential in establishing high-risk criteria. There is evidence to suggest that
individuals with BPD are likely to experience hallucinations, body image distortions, and
ideas of reference, especially during stressful periods (Thompson et al., 2012). The
prevalence rates for BPD in high-risk individuals are inconsistent with reports as low as
5% or as high as 17% (Lencz et al., 2004; Rosen et al., 2006). More recently Ryan et al.
(2017) reported prevalence rates of 25%. Although Rosen and colleagues found
prevalence rates of 17% for BPD, there was no difference in prevalence rates of their
high-risk sample compared to their control sample. Based on these findings, it remains
unclear if there is a true difference in presentation of this disorder and how it contributes
to our understanding of personality disorder pathways that may be linked to the
development of psychosis.
Thompson and colleagues attempted to further explore these issues, finding that
there was no difference in the rates of transition to psychosis in individuals with baseline
BPD compared to those without the diagnoses. In addition, reports of BPD symptoms at
baseline were not related to the onset of a particular psychotic disorder.
With limited research, it still remains unclear as to whether or not there is a
distinction between individuals whose high-risk symptoms are manifested in their
personality framework and individuals who are truly at risk for psychotic disorders. This
study hopes to clarify how personality disorders present in different high-risk stages.
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Attenuated Positive and Negative Symptoms
Individuals who are high-risk for psychosis may experience attenuated positive
and negative symptoms in addition to psychological difficulties which may induce further
distress. While there is considerable research on how positive and negative symptoms
present and develop in this population, less is known about the relationship between
attenuated symptoms and co-occurring psychiatric disorders (Carrion et al., 2016; Davies
et al., 2018, Lencz et al., 2004).
Anxiety and mood disorders have been found to be strongly associated with
attenuated positive symptoms and negative symptoms (Addington et al., 2011). Some
studies suggest that high-risk individuals who meet criteria for anxiety disorder or
depression are more likely to endorse worsening negative symptoms (Falkenber et al.,
2015; McAusland et al., 2015). Individuals who meet criteria for anxiety disorders,
depressive disorders, or both are more likely to endorse attenuated positive symptoms
such as suspiciousness (McAusland et al., 2017). There is also evidence to support that
anxiety disorders are related to certain attenuated positive and negative symptoms such as
hallucinations and withdrawal, and blunted affect (Lysaker & Salyers, 2007).
Few studies have explored the relationship between substance use and attenuated
symptoms. One longitudinal study examining the relationship between substance use and
clinical measures found a link between cannabis use and hallucinations/perceptual
disturbances which are positive symptoms. In this study it was also observed that positive
symptoms worsened with increase in cannabis use and improved or remitted when highrisk individuals stopped cannabis use altogether (Corcoran et al., 2008). Similarly,
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findings from Wade et al (2007) determined that heavy substance use was associated with
attenuated positive symptoms.
Cluster A personality disorders (schizoid, schizotypal, paranoid personality
disorders) share symptoms that may overlap with attenuated positive and negative
symptoms. In particular, schizotypal personality disorder is used as a marker to identify
individuals who are high-risk for psychosis and is characterized by positive symptoms
such as suspiciousness, odd thinking, perceptual disturbances and negative symptoms
such as inappropriate affect, diminished emotional expression, social anhedonia, and
avolition (Esterberg et al., 2010). Zoghbi and colleagues confirmed this in a study
consisting of a sample where SPD was highly prevalent and found to be associated with
attenuated positive and negative symptoms (Zoghbi et al, 2019). A defining feature of
paranoid personality disorder is suspiciousness, which is a positive symptom and schizoid
personality disorder consists of negative symptoms such as avolition, flat affect, and
social anhedonia (American Psychiatric Association, 2000). As these personality
disorder traits present with similar features of positive and negative symptoms, it is
expected that Cluster A personality disorders will be associated with attenuated positive
and negative symptoms.
Studies exploring the relationship between attention-deficit and disruptive
behavior disorders and attenuated symptoms in high-risk populations are scarce. There is
evidence to suggest that high-risk individuals with these disorders are emotionally labile,
present with disorganized communication, and are inattentive which are similar features
of positive and negative symptoms (Miller et al., 2002). One study investigating social
and behavioral problems on the CBCL found that the Withdrawn/Depressed scale closely
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resembled negative symptoms and the Thought Problems scale resembled positive
symptoms and are useful instruments for identifying at-risk youth (Simeonova et al.,
2014).
In this study we hope to further explore the relationships between psychiatric
disorders and attenuated positive and negative symptoms. We expect that psychiatric
disorders will be associated with higher levels of attenuated positive and negative
symptoms. We also hope our findings will help to further clarify these relationships.
Social and Role Functioning
For many high-risk individuals, social and role functioning difficulties manifest
before first-episode psychosis and the impact may be more noticeable than the actual
attenuated positive and negative symptoms (Addington & Addington, 2005). The
development of high-risk symptoms may cause individuals to isolate themselves from
peers, feel “othered”, and disconnected from themselves. These symptoms may also
impact academic achievement, success, and completing tasks for work and school.
Although social and role functioning is widely studied in high-risk individuals, less is
known about the relationship between functioning and psychiatric disorders in this
population. Based on the pre-existing literature, we do expect there to be lower levels of
social and role functioning associated with mood disorders, anxiety disorders, attentiondeficit and disruptive behavior disorders, and personality disorders.
Earlier studies on the prodrome have cited impairments in social and role
functioning in conjunction with mood and anxiety disorders to be defining characteristics
of the prodrome (Yung and McGorry, 1996). Comorbid anxiety and depressive disorders
coupled with the at- risk symptoms have an adverse impact on baseline functioning levels
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in the participants. For anxiety disorders, social anxiety in particular is associated with
lower levels of social functioning. (Chudleigh et al. 2011). One study clarifying this
relationship suggests that dysphoric mood is associated with lower levels of role and
social functioning (Fulford et al, 2013). It has also been found among CHR participants
that participants with current and past depressive histories present with more significant
impairments in social functioning compared to those participants who did not have a
history of depression (Kline et al., 2018). The experience of anxiety and mood disorders
could further exacerbate social functioning deficits, leaving individuals feeling
dissatisfied with their social connections. Additionally, less severe mood and anxiety
disorders are associated with improvement in both social and role functioning, suggesting
that anxiety and mood disorders may indeed be contributors to social and role function
deficits in high-risk groups (Schlosser et al., 2012).
Attention-deficit and disruptive behavior disorders are also associated with lower
levels of social and role functioning in adolescents, evidenced by deficits in executive
functioning and emotional processing. Individuals in the prepsychotic phase may display
low frustration tolerance, impulsive behavior, have difficulties with focus and attention
making it difficult to perform well in school and maintain close connections with peers
(Cadesky, Mota, & Schachar, 2000; Marsh & Williams, 2006).
In examining the relationship between substance use and functioning, Auther and
colleagues compared substance use in CHR participants to healthy controls. Lifetime
CHR cannabis users reported higher social functioning, CHR cannabis users had higher
social functioning compared to nonusers at follow-up and reported no significant
differences in role functioning (Auther et al., 2012). In another study, adolescents who
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had an earlier onset of cannabis use disorder (before age 15) demonstrated better social
functioning and were more likely to perform poorly academically (Compton et al., 2011).
Similarly, in another study, early onset of cannabis use was associated with higher levels
of social functioning compared to nonusers (Bagot, Milin, & Kaminer, 2015). Based on
these findings, it appears that cannabis use is related to better social functioning.
Personality disorders impact the ability to get along with others and perform well
academically and in work environments. The role of social and role functioning is
included under the general diagnostic criteria in the DSM-IV-TR (American Psychiatric
Association, 2000) specifying that this “enduring pattern leads to clinically significant
distress or impairment in social, occupational, or other important areas of functioning ”
(p.689). However, this is not specifically included as diagnostic criterion for each of the
personality disorders. Oltmanns and colleagues explored the relationship between social
functioning and personality disorders. In a sample of 577 participants, 33% met criteria
for a personality disorder. Results indicated that impairment in social functioning is
associated with personality pathology. More specifically, participants who endorsed a
Cluster A personality disorder (paranoid, schizoid, and schizotypal) also reported lower
social functioning (Oltmanns et al., 2002).
Predictors of Conversion
Although the majority of individuals in a high-risk sample do not transition to
psychosis it is still imperative to identify these predictors to inform early intervention
treatment and also provide important information about converters and non-converters.
Several studies highlight that positive symptoms are the most robust and reliable
predictors of conversion (Cannon et al., 2008; Gee & Cannon, 2011; Ruhrmann et al.,
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2008; Yung et al., 2003). A study analyzing baseline demographics and clinical
predictors of psychosis in a CHR sample, reported that higher SIPS scores on positive
symptoms were predictive of conversion, suggesting that the severity of positive
symptoms may be associated with more severe psychosis. (Zhang et al., 2017).
There is evidence to support that anxiety disorders are not predictors of
conversion. In a large-scale study of 509 at-risk subjects, exploring comorbid diagnoses
and their impact on transition outcomes, it was found that anxiety disorders did not have
an impact on transition to psychosis (Fusar-Poli et al., 2014). In another study conducted
by McAusland et al (2014), 51% of CHR participants met criteria for an anxiety disorder
but anxiety disorders did not predict transition to psychosis.
Mood disorders have been proven to be predictors of conversion. In an EPOS
study, bipolar and depressive disorders were shown to predict conversion to psychosis
over anxiety disorders (Salokangas et al., 2012).
Specifically, with cannabis use, the research findings on the association between
use and transition to psychosis have been inconsistent. Phillips and colleagues did not
find that cannabis use or dependence impacted transition to psychosis (Phillips et al.,
2002). Similarly, another study, conducted by Buchy and colleagues with a sample of 170
CHR subjects found that cannabis use did not predict later conversion to psychosis
(Buchy et al., 2014). Additionally, low to moderate lifetime cannabis was found not to
predict transition to psychosis in another sample (Auther et al., 2012). Yung et al., 2004
also did not find an association between conversion to psychosis and cannabis abuse.
Auther et al. (2015) also found that cannabis use and abuse were not predictive of
conversion
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Other studies have found a link between cannabis use and transition to psychosis.
One study found that age of onset of cannabis use was associated with onset of high-risk
symptoms suggesting that cannabis use may play a role in the development of psychosis
(Dragt et al., 2012). Similarly, another study found that early onset of cannabis use
(before age 15), frequency of use, and continued use were associated with transition to
psychosis (Valmaggia et al., 2014).
Regarding other substances, there are mixed findings on the association between
nicotine use and conversion. Kristensen & Cadenshead (2007) observed a line between
nicotine use and conversion. In this same study, among the 6 participants who converted
to psychosis, 4 of them smoked cigarettes. Similarly, Weiser et al. (2004) observed that
the risk for schizophrenia was higher in adolescents who smoked at least one cigarette a
day. Additionally, there was a significant association between the number of cigarettes
smoked and the risk for psychosis as higher nicotine use was associated with higher- risk
for psychosis. However, Zammit et al. (2003) found low rates of transition to psychosis
among cigarette smokers
Course of Axis I and Axis II Disorders
Although the above studies have been instrumental in providing information
about the occurrence of Axis I disorders in high-risk individuals, less is known about how
these disorders impact long-term outcomes. Some studies that have attempted to address
this issue through longitudinal studies. McAusland and colleagues (2017) found that 51%
of their sample met criteria at the 24-month follow up for anxiety disorder with several
participants presenting with more than one anxiety disorder.
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Lin et al. (2015) investigated the comorbidity rates of nonpsychotic diagnoses in
high-risk individuals at the 12-month follow-up and found high prevalence rates of
depressive and anxiety disorders at follow-up of 48.7% and 34.5% respectively.
Participants meeting criteria for more than one disorder at follow-up presented with more
severe symptoms, higher distress, and lower functioning. In their study, 68.1 % of their
at- risk participants met diagnostic criteria for at least one Axis I disorder at the 7-year
follow-up period with mood disorders (48.7%), anxiety disorders (34.5%), and substance
use disorders (29.2%) being the most common. In this sample, comorbid mental disorders
had the tendency to persist or recur (51.6% persistent/recurring vs. 26.0% remittent
course). Specifically, mood disorders (38.4%) and then followed by anxiety disorders
(16.2%) were the most persistent /recurrent disorders. Incident diagnoses developed in
37.5% of participants and 7.3% had no diagnoses. Comorbid disorders were associated
with lower GAF scores at one-year follow-up. These findings suggest that Axis I
disorders tend to persist over time and are correlated with functioning deficiencies. This
dissertation study will follow the methodological approach described by Lin et al. (2015)
to explore the developmental course of psychiatric disorders in the RAP sample.
We expect to have similar findings with anxiety and mood disorders being the
most persistent and recurrent in this study. We will further expand on Lin et al and
colleagues’ study by also assessing the progression of psychiatric disorders using the
clinical staging RAP model and comparing progression of disorders in the RAP
subgroups. Additionally, we added attention-deficit and disruptive behavior disorders
and personality disorders to our analyses to explore the progression of these disorders.
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Aims and Hypotheses
Aim 1: Examine the baseline prevalence rates of psychiatric disorders in the
sample of CHR participants (CHR + and CHR- groups) in the RAP Program. This
study will determine if there are differential rates of psychiatric disorders
between the RAP prodromal groups (CHR-, CHR+) compared to each other. This
study will also assess the relationship between psychiatric disorders and
attenuated symptoms and functioning.
Aim 2: Examine the long-term stability of psychiatric disorders in CHR
participants in the RAP Program. Determine if there are differential rates of
stability (persistent/recurrent, remitted, incident, and never present) of psychiatric
disorders for the RAP high-risk groups (CHR-, CHR+).
Aim 3: Identify whether positive symptoms predict conversion over and above
Axis I disorders.
Hypotheses for Aim 1
Hypothesis 1: There will be no differences in rates of comorbid psychiatric
disorders between the RAP prodromal groups (CHR- and CHR+).
Hypothesis 2: Comorbid psychiatric disorders will be related to higher attenuated
positive and negative symptoms, poorer social/role functioning scores at baseline.

Hypothesis for Aim 2
Hypothesis 3: In comparison to other psychiatric disorders, mood and anxiety
disorders will be persistent/recurrent from baseline to last follow-up for both
high-risk subgroups.
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Hypothesis for Aim 3
Hypothesis 4: Attenuated positive symptoms will be a significant predictor of
conversion to psychosis over and above Axis I disorders at baseline. Additionally,
of all the Axis I disorders, mood disorders at baseline will be the strongest
predictor of conversion.
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Chapter 3: Methods
Ethics in Research
This study used previously collected data by the Recognition and Prevention
(RAP) Program and was therefore determined to be exempt by St. John’s University’s
Institutional Review Board (IRB: #1118 143), which reviews all research for compliance
with ethical guidelines. Researcher was also granted permission to use data for
dissertation by P.I. Dr. Barbara A. Cornblatt, Ph.D., M.B.A.
Participants
Participants were 156 (110 males and 46 females) who participated in the
Recognition & Prevention (RAP) Program during Phase I (2000-2006). The RAP
Program has been continuously funded by the National Institute of Mental Health
(NIMH) since 2000. It is located at The Zucker Hillside Hospital (ZHH) which is part of
the Northwell Health hospital system in New York. The RAP Program conducts research
and provides interventions for adolescents and young adults who present in the prodromal
or high-risk stage of psychotic illness.
All participants were help-seeking individuals referred from health care providers
in the inpatient and outpatient psychiatry departments at ZHH, from private practitioners
in the community, or were self-referred. Participants between the ages of 12-22 years of
age were recruited for this study if they met criteria for one of the CHR categories:
Clinical High Risk Negative (CHR-) and Clinical High Risk Positive (CHR+). High risk
participants were included in the RAP Program research based on the presence of
attenuated positive and negative symptoms as assessed by the SOPS measure.
Participants with at least one attenuated negative symptom at a moderate (score of 3) or
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higher level, but with no attenuated positive symptoms, were classified as Clinical High
Risk – Negative (CHR -). Participants with at least one attenuated positive symptom in
the moderate (score of 3) to severe (score of 5) range were classified as Clinical High
Risk – Positive (CHR+). The final category of the RAP model is the Schizophrenia-like
Psychosis (SLP) group, defined as a person who has a positive symptom that has reached
a psychotic level (score of 6). This is thought to be an intermediate stage between the
prodrome (CHR- and CHR+ groups) and a full diagnosis of schizophrenia. Please see
Figure 2. Note that in this dissertation, the SLP group will not be used.
Participants were excluded from the study if they met criteria at baseline for a
diagnosis of a schizophrenia-spectrum disorder (i.e. schizophrenia, schizophreniform
disorder, schizoaffective disorder, delusional disorder), a mood disorder with psychotic
features, or a bipolar spectrum disorder. Participants were also excluded if they had lack
of English fluency, an estimated IQ <70, or a diagnosis of a medical or neurological
disorder known to affect the developing brain.
Procedures
Participants who met criteria for the study were informed of the research
protocol, given the opportunity to ask questions, and were invited to participate in the
study. Written informed consent was obtained from participants 18 years of age and
older or from a parent or guardian if participant was under the age of 18 (in addition to
written assent). Participants were informed that their participation in the study was
voluntary and that they could withdraw from the study at any time.
For this study, confidentiality was maintained by the assignment of subject
numbers to participants in the study. Data collected from participants were kept in
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locked file cabinets at Zucker Hillside Hospital. Risks associated with participation in
this study include possible fatigue or discomfort when responding to questions especially
over a lengthy period of time. Benefits of participation in this research include
identification of disorders that may be impacting the individual’s functioning. This
information could also be used to help the individual secure a referral for treatment.
Other benefits include advancing our knowledge and understanding of individuals who
are at-risk for psychosis with the hope of identifying effective forms of treatment. All
procedures were approved by the IRB at Northwell Health.
Testing procedures consisted of a battery of clinical, behavioral, functional, and
neurocognitive measures taking approximately 3.5 hours that were collected at baseline
and approximately every 6 months for up to 5 years. Average length of follow-up is 2.9
years and therefore had varying follow-up times. Participants were compensated $10 an
hour for their time and effort while participating in the research procedures. For the
purposes of this dissertation, only data concerning prodromal symptoms, Axis I and Axis
II disorders, and social and role functioning obtained via structured clinical interviews
will be analyzed.
Generally, parents/guardians were interviewed before the participant as they could
provide useful information that could be used when interviewing participants. After
interviewing the parent/guardian, the assessor interviewed the participants, noting and
reconciling any discrepancies in the reports. Assessors were all at the master’s level or
above and were trained in administration and scoring of all the measures. Once
completed, interviews were then scored by the interviewer and presented to an expert
diagnostician at a consensus meeting.
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Measures
Demographic Variables. Age, sex, and US census-based race and ethnicity
categories were obtained for each participant. Subjects and their guardians provided
demographic information regarding age, sex, racial/ethnic identification, education, and
annual household income. The instruments show good face validity and are typical of
those used for research in hospital settings. Estimated IQ was obtained by administering
the Vocabulary and Block Design subtests from the Wechsler Intelligence Scale for
Children-Third Edition (WISC-III; Wechsler, 1991) and the Wechsler Adult Intelligence
Scale-Revised (WAIS-R; Wechsler, 1981) depending on the age of the participant.
Assessment of High-Risk Symptoms. The (SOPS) and its companion Structured
Interview for Prodromal Symptoms or (SIPS) were developed by McGlashan and
colleagues to assess symptoms for identifying prodromal states (McGlashan et al., 2010).
The SOPS contains five items measuring positive symptoms (unusual thought content,
suspiciousness, grandiosity, perceptual abnormalities, speech disorganization), six items
measuring negative symptoms (social isolation, avolition, decreased expression of
emotion, decreased experience of emotion, decreased ideational richness, decreased role
functioning), four items measuring disorganization symptoms (odd appearance, bizarre
thinking, poor focus/attention, poor hygiene), and four items measuring general
symptoms (sleep disturbance, dysphoric mood, motor disturbance, decreased stress
tolerance). These symptoms are rated on a 7-point anchored scale ranging from 0 (not
present) to 6 (psychotic or extreme intensity). According to Miller et al (2003), the SOPS
has good internal consistency with a Cronbach alpha coefficients above 0.75 for all
subscales.
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The Schedule for Affective Disorders and Schizophrenia for School-Age
Children, Epidemiologic Version. The K-SADS-E is a semi-structured interview that
uses both child and parent interviews to diagnostically assess current and lifetime
disorders such as affective, anxiety, behavioral, psychotic disorders, and substance use
disorders (K-SADS-E; Orvaschel & Puig-Antich, 1994). Current episodes are rated on a
severity scale and identified as mild, moderate, or severe and past episodes are rated as
absent or present. Ratings are based on specific DSM-IV criteria for each disorder
assessed (Ambrosini et al., 2000). The KSADS-E has been found to have good internal
consistency of its scales, with reported Cronbach alpha coefficients between .51 and .75
for its subscales (Ambrosini et al., 2000).
The Structured Interview for the Diagnosis of Personality for DSM- IV. The
SIDP-IV assessed personality traits/disorders (SIDP-IV; Pfohl, Blum, &Zimmerman,
1995). This semi-structured interview assesses the diagnostic criteria for the 10
personality disorders in the DSM-IV (i.e. paranoid, schizoid, schizotypal, borderline,
narcissistic, histrionic, antisocial, avoidant, dependent, and obsessive-compulsive).
Questions are arranged by themes instead of by disorders (e.g. interpersonal relationships,
emotions, interests) and each criterion is rated on a scale from 0 to 3. Each item
represents a specific symptom or trait associated with a disorder and is rated as 0 (not
present or limited to rare isolated examples), 1 (subthreshold-some evidence of the trait
but is not sufficiently pervasive or severe to consider the criterion present), 2 (presentcriterion is clearly present (at least 50% of the time) for most of the last 2 years), or 3
(strongly present- criterion is associated with subjective distress or some impairment in
social or occupational functioning or intimate relationships.) In order to receive a
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diagnosis for a personality disorder, the participant must meet the required number of
symptoms for that particular personality disorder at either the “present” or “strongly
present” level. The SIDP-IV has good internal consistency, with a Cronbach alpha
coefficient of at least 0.70 for it’s scales (Jane et al., 2006).
Global Functioning: Social (GF:Social) and Role (GF:Role) scales. Social and
role functioning were assessed using these measures. These scales account for age and
phase of illness and detect functional changes over time. Unlike other scales, these scales
avoid confounding functioning with psychiatric symptoms. The GF: Social scale assesses
peer relationships, peer conflict, age-appropriate intimate relationships, and involvement
with family members. The GF: Role scale rates performance level and amount of support
needed in one’s specific role (i.e., school or work). For both scales, scores range from 1
(extreme dysfunction) to 10 (superior functioning) and anchors are provided at each
increment. Ratings for each of the scales were obtained from clinical information based
on clinician reports and interviews (Cornblatt et al., 2007). The Global Functioning:
Social (GF:Social) and Role (GF:Role) scales have excellent internal consistency with a
Cronbach’s alpha coefficient of above 0.80 for both scales (Cornblatt et al., 2007).
Research design and analysis. All statistical procedures were calculated using
SPSS version 22.
Missing data. Before performing any analyses, the categorical and continuous
variables were checked for any errors that may fall outside of the possible range of
values, as this may distort future analyses and were also checked for missing values. Data
were missing for NAPLS IQ (7.7%) and for Sum total of negative symptoms (13.5%). It
was determined that the data was missing completely at random and expectation
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maximization was imputed to assign missing values (Dempster, Laird, N., & Rubin,
1977).
Preliminary analysis. Descriptive statistics were calculated for basic
demographic comparisons on gender, age, IQ, and race between RAP subgroups (CHR-,
CHR+). Chi squares were computed for categorical variables (gender and race) and
ANOVAs for continuous variables (age and IQ).
Statistical Analyses. Axis I disorders will be analyzed individually and collapsed
into the following summary categories: mood disorders, anxiety disorders, substance use
disorders, and other disorders. Axis II disorders will be collapsed into 3 clusters (Cluster
A, Cluster B, Cluster C) in addition to being examined as individual personality disorders
(10 disorders).
For Hypothesis 1, Chi-square analyses will be used to compare the prevalence
rates for the above-mentioned groupings of Axis I and Axis II disorders at baseline
between the prodromal groups (CHR- and CHR+; Hypothesis 1).
For Hypothesis 2, the association between psychiatric disorders (mood, anxiety,
substance use, and attention-deficit and disruptive behavior disorders ), functioning
(social and role functioning), and attenuated symptoms (positive and negative symptoms)
will be tested by evaluating correlations between these variables for CHR- and CHR+
groups separately. If significant correlations are found between the variables, then this
will be followed up with ANOVAs to determine if there are differences in functioning
(social or role functioning) based on psychiatric disorders and by group status
(CHR+/CHR-). For these analyses, independent variables (psychiatric disorders and CHR
group status) and dependent variables (social/role functioning, attenuated symptoms) will
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be entered into the models to determine if there are significant differences in functioning
and attenuated symptom presentation based on type of psychiatric disorder and CHR
group status. To reduce Type 1 Error, the critical p value will be adjusted to account for
multiple comparisons (p < 0.01).
For Hypothesis 3, we will evaluate the stability of Axis I and II disorders, by
following the methodological approach illustrated by Lin et al. (2015). To examine the
course of the Axis I and II disorders, participants will be organized into four different
categories. If the disorder was not present at baseline and follow-up, it will be categorized
as “not present.” If the disorder was present at baseline and follow-up, it will be classified
as “persistent/recurrent”. Disorders that were present at baseline but absent at follow-up
will be labeled “remitted” and disorders that were present at follow-up but absent at
baseline will be classified as “incident” cases. The frequencies of each category will be
obtained for CHR- and CHR+ groups separately and compared by psychiatric disorders.
For Hypothesis 4, we will assess predictors of conversion by first examining the
association between conversion and the SOPS scale (positive symptoms, negative
symptoms, disorganized symptoms, and general symptoms) by calculating correlation
coefficients. The coefficients found to be significant at the p<.01 level would then be
entered into the binary logistic regression model in conjunction with Axis I disorders
(mood, anxiety, substance use, attention-deficit and disruptive behavior disorders) to
identify predictors of conversion.
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Chapter 4: Results
This chapter offers an overview of the results of preliminary analyses such as
descriptive statistics of the CHR+ and CHR- groups. It also reports the findings of chisquare analyses, ANOVAs, and regression analyses used to analyze clinical and
functional outcomes for the two high-risk groups.
Demographics and Clinical Characteristics
Demographic and clinical characteristic information for the CHR subgroups are
presented in Tables 1.1, 1.2. There were one hundred and fifty-six participants in this
sample (110 males and 46 females). Frequencies were obtained assessing group
differences based on gender and ethnicity. Results indicated that males were a larger
proportion of this sample (70.5%) compared to females (29.5%). When considering
CHR group status for demographics, the CHR+ subgroup consisted of 65 males (64.4%)
and 36 females (35.6%). In the CHR- group, 45 participants identified as male (81.8%)
and 10 (18.2%) identified as female. Significant differences on gender were found at the
.05 level F (1,154)=5.334, p= .022. In terms of ethnicity, participants described
themselves as mostly White (n = 122, 78.2%), Black (n =14, 9.0%), Asian (n =14, 9.0%),
and Other/Mixed (n =6, 3.8%) and there were no significant differences found for
ethnicity.
ANOVAS were performed to compare the differences in age, IQ, total positive
symptoms, total negative symptoms, total disorganized symptoms, total generalized
symptoms, social functioning, and role functioning between the high-risk groups.
Participants were between the ages of 12 and 22 (M = 15.97, SD = 2.14). No significant
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differences were found for age

F (1,154)=.589, p= .444 or IQ F (1,142) = .224, p

=.637 between the CHR subgroups.
Participants completed the SOPS which measured total positive, negative,
disorganized, and general symptoms. Generally, there was a trend of CHR+ participants
scoring higher compared to CHR- participants on these scales. Significant differences
were found for the report of positive F (1,154)=150.482, p=.000 and negative symptoms
F (1,154)=8.659, p= .004. These results are expected given that assignment to the CHR
groups are based on the presence of attenuated positive and negative symptoms. There
were also significant differences in the report of disorganized symptoms at the .05 level
F (1,154)=.414, p= .004.
In assessing functioning between the two RAP subgroups, significant differences
were found for social functioning F (1,154)=7.991, p=.005 but not for role functioning
F(1,154) =.320, p = 573.
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Table 1.1
Demographics for Entire Sample

Gender
Male
Female
Ethnicity
White
Black
Asian
Other/Mixed

Frequency
(n)

Percentage
(%)

110
46

70.5
29.5

122
14
14
6

78.2
9.0
9.0
3.8

Table 1.2
Descriptive Statistics for High-Risk groups

Age
Gender, N(%)
Female
Male
Ethnicity, N (%)
Caucasian
Black
Asian
Other/Mixed
IQ
SOPS Total Positive
SOPS Total Negative
SOPS Total
Disorganized
SOPS Total General
Social Functioning
Role Functioning

CHR+
N=101
16.07 ± 2.17

CHRN=55
15.79 ± 2.09

36 (35.6%)
65 (64.4%)

10 (18.2%)
45 (81.8%)

81 (80.2%)
11 (10.9%)
7 (6.9%)
2 (2.0%)
102.85 ±
15.70
8.85 ± 3.85
12.83 ± 5.42
5.78 ±3.50

41 (74.5%)
3 (5.5%)
7 (12.7%)
4 (7.3%)
103.97 ±
15.79
1.98 ± 2.09
15.55 ± 5.70
4.42 ± 3.51

8.49 ±3.87
6.03±1.43
5.55±2.03

4.42 ± 3.51
5.40± 1.12
5.35± 2.50

p is significant at the 0.01 level
p is significant at the 0.05 level

**
*
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F

p

.589
5.334

.444
.022*

3.410

.067

.181

.671

150.482
8.659
5.414

.000**
.004**
.021*

2.209
7.991
.320

.139
.005**
.573

Hypothesis 1
Chi-square tests of independence were used to compare the prevalence rates of
psychiatric disorders between the high-risk groups (CHR- and CHR+) at baseline. To
perform these analyses, Axis I disorders were collapsed into the following categories:
mood disorders, anxiety disorders, substance use disorders, and attention-deficit and
disruptive behavior disorders. Personality disorders were collapsed into 3 clusters
(Cluster A, Cluster B, Cluster C) in addition to being examined as individual personality
disorders (paranoid, schizoid, schizotypal, antisocial, borderline, histrionic, narcissistic,
avoidant, dependent, and obsessive compulsive).
Chi-square analyses were performed to assess the relationship between high-risk
status (CHR + and CHR-) and mood disorders, anxiety disorders, substance use
disorders, attention-deficit and disruptive behavior disorders, and personality disorders.
The Fisher’s exact test was used to determine associations between the variables as one
or more expected cell counts in the crosstabulations were less than five (Sprent et al.,
2011). As displayed in Table 2.1, chi-square analyses revealed no significant differences
in the proportion of high-risk participants who report mood, anxiety, substance use
disorders, at baseline. As seen in Table 2.2, significant differences were found in
participants who met criteria for paranoid personality disorder x2 (1, n=155) = 6.954, p
=.008, schizoid personality disorder x2 (1, n =155)= 7.650, p=.006, and borderline
personality x2 (1, n= 155)= 6.330, p=.009. CHR- participants were more likely to endorse
schizoid personality disorder and CHR+ participants were more likely to report paranoid
personality disorder and borderline personality disorder.
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As seen in Table 2.1, a large proportion of CHR+ and CHR- participants reported
mood or anxiety disorders at baseline, 79.2% and 78.2 respectively. Additionally, when
diagnoses are examined separately, 62.4% of CHR+ participants and 54.5% of CHRparticipants met criteria for a mood disorder at baseline. Likewise, 54.5% of CHR+
participants and 45.5% of CHR- participants reported an anxiety disorder at baseline.
Lowest proportions among high-risk participants were reported for substance use, 8.9%
for CHR+ and 3.6% for CHR- participants. ADHD disorders were endorsed by CHR
participants, with 33.7% in the CHR+ subgroup and 25.5% in the CHR-group. As for
personality disorders, which are displayed in Table 2.2, 45.5% of CHR+ and 51.9% of
CHR- participants did not meet criteria for an Axis II disorder. Among CHR- participants
there was also a similarity in presentation of Cluster A and C personality disorders
(22.2%). Generally, a larger proportion of CHR+ participants endorsed personality
disorders compared to CHR- participants.
The results indicate that there are differences in Axis II presentation, therefore
partially supporting Hypothesis I. This further supports monitoring symptoms over time
to distinguish between the RAP subgroups.
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Table 2.1
Prevalence Rates of Axis I Disorders at Baseline

No Axis I Disorder
Any Mood Disorder
Major Depressive Disorder
Dysthymic Disorder
Bipolar Spectrum Disordera
Other mood Disorder
Any Anxiety Disorder
Agoraphobia
GAD
OCD
Panic Disorder
PTSD
Social Phobia
Specific Phobia
Other Anxiety Disorder
Any mood or anxiety
Disorder
Any substance Disorder
Alcohol Disorder
Cannabis Disorder
Cocaine Disorder
Hallucinogen Disorder
Nicotine Disorder
Polysubstance use Disorder
ADHD
Conduct Disorder
Disruptive Behavioral
Disorder NOS
Oppositional Defiant Disorder
Adjustment Disorder
Intermittent Explosive
Disorder
Learning Disorder
Developmental Disorder
Tic Disorder
a

CHR + (%)
N=161
3(3.0)

CHR- (%)
N=55
4(7.3)

Mood and Anxiety Disorders
63 (62.4)
30 (54.5)
44 (43.6)
16 (21.2)
6 (5.9)
4 (7.3)
0 (0.0)
0 (0.0)
14 (13.9)
10 (18.2)
55 (54.5)
25 (45.5)
2 (2.0)
0 (0.0)
12 (10.4)
4 (7.3)
9 (8.9)
3 (5.5)
8 (7.9)
0 (0.0)
3 (3.0)
1 (1.8)
23 (22.8)
19 (34.5)
9 (8.9)
4 (7.3)
13 (12.9)
2 (3.6)
80(79.2)
43 (78.2)
Substance Disorders
9 (8.9)
2 (3.6)
2 (2.0)
0 (0.0)
7 (6.9)
2 (3.6)
1 (1.0)
0 (0.0)
0 (0.0)
1 (1.8)
1 (1.0)
0 (0.0)
1 (1.0)
0 (0.0)
Other Disorders
34(33.7)
14(25.5)
3(3.0)
2 (3.6)
1(1.0)
0 (0)

1.538

Fisher exact pvalue
.243

.907
3.152
.105
.511
1.155
1.103
.822
.599
4.592
.189
2.509
.125
3.494
.022

.341
.087
.742
.493
.317
.541
.422
.542
.051
1.000
.132
1.000
.087
1.000

1.512
1.103
.711
.548
1.848
.548
.548

.330
.541
.494
1.000
.353
1.000
.461

1.126
.051
.548

.289
.821
.459

χ2

31(30.7)
3 (3.0)
1 (1.0)

9 (16.4)
3 (5.5)
1 (1.8)

3.835
.594
.193

.050
.441
.660

5 (5.0)
5 (5.0)
1 (1.0)

5 (9.1)
3 (5.5)
1(1.8)

1.018
.019
.193

.313
.892
.660

No participants reported Bipolar Spectrum Disorder at baseline
p is significant at the .01 level

**
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Table 2.2
Prevalence Rates of Axis II Disorders at Baseline

No Axis II
disorder
Cluster A
Paranoid PD
Schizoid PD
Schizotypal PD
Cluster B
Antisocial PDa
Borderline PD
Histrionic PDb
Narcissistic PD
Cluster C
Avoidant PD
Dependent PD
Obsessive
Compulsive PD

CHR+ (%)
N=101
46 (45.5)

CHR- (%)
N=55
28 (51.9)

χ2

Fisher exact p-value

.561

.502

25 (24.8)
12 (11.9)
7 (6.9)
11 (10.9)
11(10.9)
0 (0.0)
11 (10.9)
0 (0.0)
0 (0.0)
32 (31.7)
29 (28.7)
2 (2.0)
3(3.0)

12(22.2)
0 (0.0)
12 (22.2)
1 (1.9)
1(1.9)
0 (0.0)
0 (0.0)
0 (0.0)
1(1.9)
12(22.2)
12 (22.2)
0 (0.0)
0(0.0)

.124
6.954
7.650
4.025
4.025
6.330
.102
1.549
.762
1.083
1.636

.844
.009**
.009**
.058
.058
.009**
.348
.263
.447
.543
.552

No participants reported Histrionic PD diagnoses at baseline
No participants reported Antisocial PD diagnoses at baseline
**
p is significant at the 0.01 level
a
b

Hypothesis 2
Correlation analyses and ANOVAS were conducted to determine if there are
differences in functioning or attenuated symptom presentation by psychiatric disorder and
CHR group status. Point biserial correlation coefficients were first performed to
determine the relationships between psychiatric disorders, attenuated positive/negative
symptoms, and social/role functioning for each of the high-risk groups (CHR+ and CHR). For the CHR+ subgroup, moderate correlations were found between Cluster A
Personality Disorder and total positive symptoms (r = .268, n=101, p< .01), total
negative symptoms (r = .330, n = 101, p<.01), and social functioning (r = -.318, n= 101,
p <.01). For the CHR- subgroup, there was a moderate positive correlation between
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Cluster A personality disorder and total negative symptoms (r=.378, n=54, p<.001) and
a strong negative correlation with social functioning (r=-.557, n=54, p<.001). There was
also a moderate, negative correlation between mood and role functioning ( r= -.404, n=
55, p<.01).
For the CHR+ subgroup there were a few other significant correlations that were
obtained at the p<.01 level although not part of our research aims such as cluster C and
anxiety (r=.452, n =101, p<.01), social functioning and total negative symptoms (r=.501, n=101, p<.01), role functioning and total negative symptoms (r=-.439, n=101,
p<.01). For the CHR- subgroup there were moderate to strong correlations obtained
between Cluster C and anxiety (r=.576, n=54, p<.01) and role functioning and total
negative symptoms (r=-.416, n=54, p<.01).
Although these analyses are only focusing on significant correlations at the .01
level, it is noteworthy that there are several significant correlations at the .05 level for
CHR+ participants. These include small correlations between mood disorders and Cluster
B personality disorders (r=.206, n=101, p<.01) and substance disorders and social
functioning (r=.237, n=101, p<.01). Small, negative correlations were found between
anxiety and attention-deficit and disruptive behavior disorders (r=-.202, n=101, p<.01),
Cluster A personality disorders and role functioning (r=.203, n=101, p<.01), and Cluster
C personality disorder and social functioning (r=-.253, n=101, p<.01). See Tables 3.1,
3.2.
Overall, it appears that there are similarities in the presentation of Cluster A
personality disorder among the CHR subgroups with significant associations between
total negative and social functioning for both CHR+ and CHR- participants. Additionally,
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significant associations were found between Cluster A personality disorder and total
positive symptoms for the CHR+ subgroup and between mood disorder and role
functioning.
After determining significant associations between attenuated positive and
negative symptoms and functioning for Cluster A personality disorders and mood
disorders, additional analyses were conducted using ANOVAS to further explore if there
are differences in functioning or attenuated symptoms by disorder (Cluster A personality
disorder or mood disorder) or by CHR group status (CHR+, CHR-). These results
confirmed that role functioning has an impact on mood disorders F (1,53)=10.337,
p=.002 for the CHR-subgroup. Additionally, these follow-up analyses confirmed that
attenuated positive symptoms F (1,99)=7.632, p=.007, negative symptoms
F(1,99)=12.060, p=.000, and social functioning F (1,99)=11.136, p=.001 have an impact
on Cluster A personality disorders for the CHR+ subgroup. Similarly, for the CHRsubgroup attenuated negative symptoms F (1,53)= 8.674 p=.005 and social functioning F
(1,53)=23.424, p=.000 were found to also have an impact on Cluster A personality
disorder presentation.
These results partially support our hypothesis, as mood disorders were associated
with lower role functioning and Cluster A personality disorders were associated with
lower social functioning and attenuated negative symptoms.
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Table 3.1
Correlation Matrix for Clinical and Functional Characteristics in CHR + subgroup
M

A

S

B
.

CA

CB

CC

Pos

Neg

Soc

Mood

---

Anxiety

.152

---

Substance

.099

-.063

---

Behavioral

-.064

-.202*

.065

---

Cluster A PD
Cluster B PD
Cluster C PD
Total Pos

.019
.206*
.177
-.057

-.074
.192
.452**
.125

-.099
.114
-.064
-.024

-.144
-.077
-.131
-.107

--.020
.152
.268**

--.172
.188

--.176

---

Total Neg

.114

-.013

.032

-.004

.330**

-.045

.160

.046

---

Social Func

.002

-.121

.237*

-.024

-.318**

.015

-.253*

-.086

-.501**

---

Role Func

.011

.054

-.137

-.154

-.203*

-.064

-.081

-.056

-.439**

.187

Role

---

**Correlation coefficient is significant at the 0.01 level
*Correlation is significant at the 0.05 level

Table 3.2
Correlation Matrix for Clinical and Functional Characteristics in CHR - subgroup
M

A

S

B

CA

CB

CC

Pos

Neg

Soc

Mood

---

Anxiety

-.120

---

Substance

-.213

.018

---

Behavioral

.100

-.247

.018

---

Cluster A
PD
Cluster B
PD
Cluster C
PD
Total Pos

-.060

-.228

-.105

-.050

---

.123

-.128

-.027

-.128

-.073

---

.030

.576**

-.105

-.050

-.071

-.073

---

.133

-.080

-.045

.043

.041

.207

.150

---

Total Neg

.257

-.052

-.043

-.104

.378**

.007

-.003

.433

---

Social Func

.066

-.165

.018

.132

-.557**

-.176

-.052

.051

-.453**

---

Role Func

-.404**

.035

.130

-.187

.004

-.128

.112

-.102

-.416**

-.090

**Correlation coefficient is significant at the 0.01 level
*Correlation is significant at the 0.05 level
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Role

---

Table 3.3
Association between Mood Disorders and High-Risk Symptoms and Functioning
Predictor
CHR+

df

F

sig

Total Positive
Total Negative
Social Functioning
Role Functioning

(1,99)
(1,99)
(1,99)
(1,99)

.320
1.299
.000
.012

.573
.257
.985
.915

(1,53)
(1,53)
(1,53)
(1,53)

.959
3.733
.232
10.337

.332
.059
.632
.002**

CHRTotal Positive
Total Negative
Social Functioning
Role Functioning
p is significant at the 0.01 level

**

Table 3.4
Association between Cluster A Personality Disorders and High-Risk Symptoms and
Functioning
Predictor
CHR+

df

F

sig

Total Positive
Total Negative
Social Functioning
Role Functioning

(1,99)
(1,99)
(1,99)
(1,99)

7.632
12.060
11.136
4.240

.007**
.000**
.001**
.042

(1,53)
(1,53)
(1,53)
(1,53)

.088
8.674
23.424
.001

.768
.005**
.000**
.977

CHRTotal Positive
Total Negative
Social Functioning
Role Functioning
p is significant at the 0.01 level

**
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Hypothesis 3
Table 4.1 displays the course of psychiatric disorders for high- risk groups by
presenting frequencies of baseline, remission, incidence, persistence/recurrence, and
absence of Axis I and Axis II disorders. As seen in Table 4.1, all high-risk participants,
had a disorder present at baseline. For CHR+ participants, 34.5% had a disorder that
remitted, and 75.9% had a disorder that was persistent, and 44.8% had a new onset of a
disorder. As observed in CHR- participants, 38.5% had a disorder that remitted, 100%
had a disorder that was persistent/recurrent, and 23.1% had a new onset of a disorder.
Mood disorders. 58.6% of CHR+ participants had a mood disorder at baseline,
10.3% had a mood disorder that remitted and 48.3% had a mood disorder that was
persistent. 31.0% of CHR+ participants never had a mood disorder and 10.3% developed
a mood disorder. For CHR- participants, 30.8% had a mood disorder present at baseline,
23.1% had a mood disorder that was persistent, developed, or never present.
Anxiety disorders. For those participants with anxiety disorders, 44.8% of CHR+
participants reported an anxiety disorder at baseline, 6.9% developed an anxiety disorder
and 48.3% never had an anxiety disorder. In comparison, for CHR- participants, 53.8%
had an anxiety disorder at baseline, 7.7% had an anxiety disorder that remitted, 46.2%
had an anxiety disorder that was persistent and never had an anxiety disorder.
Substance Use. For substance use, 6.9% of CHR+ and 15.4% of CHRparticipants had a substance use disorder that was present at baseline. 6.9% of CHR+
participants had a substance use disorder that remitted, 0% had a substance use disorder
that was persistent, 93.1% of participants never had a substance use disorder and 3.4%
developed a substance use disorder. For CHR- participants, 0% had a substance use
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disorder that remitted or developed, 15.4% had a substance use disorder that was
persistent, 84.6% never had a substance use disorder. Also, substance use disorders were
more likely to be never present at baseline or follow-up.
Personality disorders. Of all CHR+ participants, 44.8% of participants had a
personality disorder present at baseline, 10.3% had a personality disorder that remitted,
61.5% had a personality disorder that was persistent, 13.8% developed a personality
disorder and 41.4% never had a personality disorder. In comparison, 61.5% of CHRparticipants had a personality disorder at baseline, 7.7% had a personality disorder that
remitted, 61.5% had a personality disorder that was persistent/recurrent, 0% developed a
personality disorder, and 30.8% never had a personality disorder.
Attention-deficit and disruptive behavior disorders. Of all high-risk participants,
51.7% of CHR+ subjects and 30.8% of CHR- subjects had an attention-deficit and
disruptive behavior disorder present at baseline. For CHR+ participants, 17.2% had an
attention-deficit and disruptive behavior disorder that remitted, and 34.5% had disorders
that were persistent, 3.4% developed one of these types of disorders, and for 37.9% of
participants, attention-deficit and disruptive behavior disorders were not present at
baseline or follow-up.
Additionally, high-risk participants developed psychotic disorders at similar rates,
with 20.7% of CHR+ participants and 23.1% of CHR- participants reporting psychosis at
follow-up.
It was hypothesized that mood and anxiety disorders would be the most
persistent/recurrent but our analyses revealed that these disorders in addition to
personality disorders and attention-deficit and disruptive behavior disorders were also
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persistent, therefore rejecting our hypothesis. It is noteworthy that for CHR- participants,
all disorders at baseline were persistent/recurrent.
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Table 4.1
The course of Axis I and Axis II Disorders
Status of Disorder
Present at baseline
Any disorder
Any mood disorder
Any anxiety disorder
Any substance use disorder
Any personality disorder
Any attention-deficit and disruptive
behavior disorder
Remitted
Any disorder
Any mood disorder
Any anxiety disorder
Any substance use disorder
Any personality disorder
Any attention-deficit and disruptive
behavior disorder
Incident
Any disorder
Any mood disorder
Any anxiety disorder
Any substance use disorder
Any personality disorder
Any attention-deficit and disruptive
behavior disorder
Any Psychotic disorder
Persistent or Recurrent
Any disorder
Any mood disorder
Any anxiety disorder
Any substance use disorder
Any personality disorder
Any attention-deficit and disruptive
behavior disorder
Never present
Any disorder
Any mood disorder
Any anxiety disorder
Any substance use disorder
Any personality disorder
Any attention-deficit and disruptive
behavior disorder

CHR +
(N=29, %)

CHR(N=13, %)

29 (100.0)
17 (58.6)
13 (44.8)
2 (6.9)
13 (44.8)
15 (51.7)

13 (100.0)
4 (30.8)
7 (53.8)
2 (15.4)
8 (61.5)
4 (30.8)

10 (34.5)
3 (10.3)
3 (10.3)
2 (6.9)
3 (10.3)
5 (17.2)

5 (38.5)
2 (15.4)
1 (7.7)
0 (0.0)
1 (7.7)
1 (7.7)

13 (44.8)
3 (10.3)
2 (6.9)
1 (3.4)
4 (13.8)
1 (3.4)

3 (23.1)
3 (23.1)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)

6 (20.7)

3 (23.1)

22 (75.9)
14 (48.3)
10 (34.5)
0 (0.0)
10 (34.5)
10 (34.5)

13 (100.0)
3 (23.1)
6 (46.2)
2 (15.4)
8 (61.5)
3 (23.1)

0 (0.0)
9 (31.0)
14 (48.3)
27 (93.1)
12 (41.4)
11 (37.9)

0 (0.0)
7 (53.8)
6 (46.2)
11(84.6)
4 (30.8)
9 (69.2)

N=42
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Hypothesis 4
Correlation analyses were performed to evaluate the association between
conversion and types of symptoms, revealing positive associations between total positive
symptoms on the SIPS and conversion (r =.26, p< .001). See Table 5.1.
A binary logistic regression was performed to assess the impact of a number of
factors on the likelihood that participants would convert to psychosis. First data were
checked to ensure that none of the assumptions were violated (sample size,
multicollinearity, and outliers). Independent variables for the model included positive
symptoms, Axis I disorders(baseline mood, baseline anxiety, baseline substance use and
baseline attention-deficit and disruptive behavior disorders). The full model containing
all the predictors was statistically significant, χ2 (5, N=101)=14.92, p <.05, indicating
that the model was able to distinguish between respondents who converted and those who
did not convert. The model as a whole explained between 13.7% (Cox and Snell R
square) and 24.2% (Nagelkerke R squared) of the variance in conversion status, and
correctly classified 88.1% of cases. As shown in Table 5.2, total positive symptoms was
the strongest predictor of conversion, with an odds ratio of 1.208. Of the baseline
psychiatric disorders entered into the regression, only the absence of a baseline mood
disorder was a significant predictor of conversion with an odds ratio of .225. Our
hypothesis is partially supported as positive symptoms were found to be the strongest
predictor of conversion, however the presence of a mood disorder predicted nonconversion to psychosis which was unexpected.
Chi-square analysis were then performed to assess the relationship between Axis
I disorder and conversion status which are all categorical variables. These results were
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statistically significant, revealing that only 35.3% of individuals with mood disorders at
baseline converted to psychosis. This analysis further supported that there is a significant
relationship between mood disorders and conversion status x2 (1, n =156)= 4.688 p=.030.

Table 5.1
Correlations between Conversion and SOPS
Conversion

Positive
Symptoms

Negative
Disorganized General
Symptoms Symptoms
Symptoms

Conversion

---

Positive
Symptoms

.263**

---

Negative
Symptoms

.171

.115

---

Disorganized
Symptoms

.202

.398**

.289**

---

General
Symptoms

-.035

.242*

.350**

.167

**Correlation is significant at the 0.01 level
*Correlation is significant at the 0.05 level
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---

Table 5.2
Logistic Regression Predicting Likelihood of Conversion
β

S.E.

Wald

df

p

Odds
Ratio

95% CI for
Odds Ratio
Lower Upper

.189

.084

5.036

1

.025

1.208

1.024

1.425

Baseline Mood
Disorder

-1.491

.650

5.267

1

.022

.225

.063

.804

Baseline Anxiety
Disorder

-.067

.654

.010

1

.919

.936

.260

3.370

Baseline
Substance
Disorder

1.040

.950

1.198

1

.274

2.829

.440

18.212

Baseline
Attention
Deficit/Disruptive
Behavior
Disorder

-.786

.743

1.118

1

.290

.456

.106

1.956

Constant

-.2689

1.060

6.431

1

.011

.068

Sum Positive
Symptoms

p is significant at 0.05 level
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Table 5.3
Baseline Axis I Disorders and Conversion
Converter
N=17
(10.9%)
Mood disorder
6 (35.3%)
Anxiety disorder
9 (52.9%)
Substance use disorder 2 (11.8%)
Attention-deficit and
6 (35.3%)
disruptive behavior
disorder

Nonconverter χ2
N=139 (89.1)

Fisher exact pvalue

87 (62.6%)
71 (51.1%)
9 (6.5%)
76 (54.7%)

.038*
1.000
.342
.197

p is significant at 0.05
level

*
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4.688
.021
.647
2.282

Chapter 5: Discussion
This current study assessed the progression of Axis I and Axis II disorders in
subjects who participated in the first phase of the Recognition and Prevention (RAP)
Program from 2000-2006. This study used the RAP model to examine the rates of
comorbidity, the development of psychiatric disorders, the relationship between
psychiatric disorders and functioning, and the clinical predictors of conversion in a CHR
sample consisting of participants who were in high- risk groups (CHR + and CHR-).
Prevalence Rates of Axis I and Axis II Disorders at Baseline
Our first hypothesis was partially confirmed and there essentially were no
differences in rates of comorbid psychiatric disorders between the CHR+ and CHRgroups. However, there are some exceptions and noteworthy findings regarding the
presentation of personality disorders. As mentioned previously, there is increasing
evidence that personality disorder pathology is present in individuals who are high risk
for developing psychosis ( Klosterkötter et al., 2001; Lim et al., 2018; Ruhrmann et al.,
2010; Ryan et al., 2015). In exploring the association between personality pathology and
high-risk status, this current study found that there are significant differences between the
high-risk groups in the presentation of borderline personality disorders, and paranoid
personality disorders, and schizoid personality disorders. Results from this study convey
that CHR- participants are more likely to meet criteria for schizoid personality disorder
and CHR+ subjects are more likely to meet criteria for paranoid personality disorder and
borderline personality disorder.
Regarding schizoid personality disorder, the symptoms are similar to the
attenuated negative symptoms associated with the CHR- subgroup. In order to meet
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criteria for the CHR-subgroup, participants must endorse at least one of the following
negative symptoms with a score of 3 or above: social anhedonia, avolition, expression of
emotion, experience of emotions and self, ideational richness, and occupational
functioning (Miller et al., 1999). Similarly, individuals with schizoid personality features
present with interpersonal, social, and affective deficits which are also consistent with the
features of negative symptoms. Those who meet criteria for this disorder appear to isolate
from others, display restricted range of emotional expression marked by flattened affect
and appear detached (American Psychiatric Association, 2000; Esterberg et al., 2010).
Earlier studies have confirmed the link between schizoid personality symptoms and
negative symptoms (Cannon et al., 1990; Cuesta et al., 1999; Cuesta et al, 2002). Peralta
et al. (1991) explained that “the negative schizophrenic symptoms are merely the
persistence or exacerbation of schizoid traits present prior to the emergence of psychotic
symptoms”, (p.338). This overlap in symptomatology explains why participants in the
CHR- subgroup were more likely to present with schizoid personality disorder and
further supports that symptoms associated with schizoid traits are early manifestations of
negative symptoms.
Subjects in the CHR+ group were more likely to meet criteria for paranoid
personality disorder which is consistent with the positive symptom classification of this
disorder. For CHR- participants to meet criteria for paranoid personality disorder would
imply that subjects endorsed at least one attenuated positive symptom which by definition
conflicts with the CHR- subgroup category (Lencz et al., 2004). Attenuated positive
symptoms that overlap with paranoid personality disorder include suspiciousness and
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mistrust of others, and unusual thought content (American Psychiatric Association, 2013;
Esterberg et al., 2010; Miller et al., 1999).
Results also indicated that participants in the CHR+ subgroup were more likely to
endorse borderline personality disorder compared to those in the CHR-subgroup. As
stated previously, there is shared symptom presentation between borderline personality
disorder and attenuated positive symptoms which may make it challenging to distinguish
between personality pathology and psychosis pathology (Ryan et al., 2017; Thompson et
al., 2012). A fairly recent study conducted by Paust and colleagues in 2019 also
confirmed this position. This study examined borderline personality symptoms and
transition to psychosis in a sample of at-risk youth. Borderline personality dimensions
were assessed using the Borderline Symptom Checklist (BSL-95) and results supported
that positive symptoms such as unusual thought content, suspiciousness/persecutory
ideas, and hallucinations were strongly correlated with BSL scores (Paust et al., 2019)
Overall, the overlap in personality pathology symptoms with attenuated positive
or negative symptoms suggests that additional longitudinal studies are necessary to
clarify the relationship over the long term, especially for those who do not develop
psychosis. The latter group of non-converters may represent false positives for psychosis
who were inaccurately classified as high risk for psychosis. Furthermore, it may be
beneficial to screen individuals who present with paranoid, schizoid, and borderline
personality pathology for high-risk status given that some studies (although not this one)
find an association between these disorders and psychosis. Lastly, these findings have
important treatment implications as interventions will need to address all comorbidities
and could inform specific treatment interventions.
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Additionally, there is evidence of an observed difference in the presentation of
oppositional defiant disorder (ODD) x2 (1, n =155)= 3.835 p=.050, between the CHR
subgroups, as CHR+ participants (30.7%) were more likely to meet criteria for ODD
compared to CHR- participants (16.4%). The research specifically on ODD and high-risk
is scarce but there are a few studies that do report prevalence rates of ODD between 2-5%
(Addington et al., 2017; Preda et al., 2002; Staddard et al., 2010). A recent longitudinal
study, assessing psychiatric diagnoses in children and adolescents from age 8 to 13
determined that ODD was associated with psychotic experiences in adults (Siebald et al.,
2016). While there appears to be some association between ODD and high-risk for
psychosis, additional studies may be able to elucidate the relationship between ODD and
the CHR+ subgroup.
Although no significant associations were found between high-risk subgroup and
Axis 1 diagnoses, the chi-square analyses display frequencies offering exploratory
information regarding baseline diagnoses presentation within the high-risk groups.
Consistent with previous studies, mood and anxiety disorders were the most prevalent at
baseline (Addington et al., 2011; Fusar-Poli et al., 2014; Lencz et al., 2004; Lin et al.,
2015). For the CHR+ subgroup 62.4% of participants met criteria for a mood disorder,
and 54.5% endorsed a mood disorder in the CHR- subgroup. These results are also
consistent with previous findings that MDD is typically the most prevalent mood disorder
diagnosis among CHR participants (Kline et al., 2018; Lin et al., 2015; Meyer et al.,
2005; Rosen et al., 2005). For anxiety disorders, 54.5% of subjects were in the CHR+
subgroup and 45.5% were in the CHR- subgroup. There were similar rates for combined
mood and anxiety disorders (CHR+ = 79.2, CHR- = 78.2). This is also consistent with the
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current research that individuals at-risk for psychosis present with combined anxiety and
affective disorders. Additionally, social phobia was the most prevalent anxiety disorder
(CHR+ = 22.8%, CHR- = 34.5%) which supports previous studies (Hui et al., 2013;
McAusland et al., 2017; Meyer et al., 2004).
There is evidence to support that CHR subjects endorse attention-deficit and
disruptive behavior disorders. For ADHD prevalence rates were (CHR+ = 33.7% and
CHR- = 25.5%) and as stated previously for oppositional defiant disorder (CHR+ =
30.7% and CHR- =16.4%). While there were no significant differences in occurrence of
attention-deficit and disruptive behavior disorders , these results support previous studies
that they are present in the CHR population (Meyer et al., 2005; Thompson et al., 2015).
Surprisingly, there were lower rates of substance use disorders observed in this sample
(CHR + = 8.9% and CHR- =3.6% compared to previous studies.
Association Between Attenuated Positive and Negative Symptoms and Functioning
in Axis I and Axis II disorders
Our study supported previous findings that Cluster A personality disorders
(paranoid, schizoid, schizotypal) are associated with impaired social functioning
(Fonseca-Pedrero et al., 2010; Henry et al., 2008; Oltmanns et al., 2002). These findings
are expected as individuals who meet criteria for these disorders often present in a
socially dysfunctional manner which deviates from the norm (Esterberg et al., 2010).
Individuals with paranoid personality disorder may be considered odd or eccentric and
may lack close relationships due to mistrust of others. Those who meet criteria for
schizoid personality disorder may present with detachment from social relationships and
restricted range in emotional expression. Lastly, individuals with schizotypal personality
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disorder may lack a desire to form close interactions and may find it challenging trying to
relate to others (American Psychological Association, 2000). Additional studies have
found that individuals who meet criteria for Cluster A personality disorders also present
with persistent decline in social functioning (Oltmanns et al., 2002; Seivewright et al.,
2004). These findings suggest that it is important to take into account social functioning
when assessing personality pathology presentation.
Cluster A personality disorders were found to be associated with attenuated
negative symptoms for both the CHR- and CHR+ subgroups. Expectedly, for the CHR+
group, there was a significant correlation between attenuated positive symptoms. Cluster
A personality disorders are grouped together by shared positive and negative traits. A
possible explanation for the shared presentation in negative symptoms may be an overlap
between the social anhedonia scale and social functioning. As explained by PelletierBaldelli et al 2021 “it may be that reduced capacity to experience pleasure leads to
diminished seeking out of interpersonal situations” (p. 101).
Notably, significant moderate associations were also found between social functioning
and negative symptoms for both subgroups. Negative symptoms have proven to be a
determinant of social functioning based on previous studies. In a sample consisting of
167 CHR individuals, Fulford et al (2013) showed that severity of negative symptoms
was significantly predictive of social functioning at baseline and follow-up. Furthermore,
another study found negative symptoms to be a mediator between social function and
global neurocognition (Meyer et al., 2014). Schlosser and colleagues also found negative
symptoms to be a significant predictor of social functioning above and beyond mood
symptoms. Additionally, experiential negative symptoms such as avolition, anhedonia
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were more predictive of social functioning in comparison to expressive symptoms
(emotional expressivity and alogia) perhaps suggesting that avolition and anhedonia are
important determinants of social functioning. Additionally, experiential negative
symptoms were also found to be a mediator between expressive symptoms and social
functioning (Schlosser et al. 2015). These results imply that it could be beneficial to
create targeted social interventions for high-risk participants.
Results also showed a strong association between Cluster C personality disorders
and anxiety disorders which is supported by previous studies. As mentioned by Brandes
& Bienvenu (2006), Cluster C is referred to as the ‘anxious cluster’ comprising of
avoidant personality, dependent personality, and obsessive compulsive personality
disorders. While anxiety disorders are co-occuring in individuals who meet criteria for
personality disorders, the highest proportion appears to be among those with Cluster C
personality disorders (Bienvenu, O. J., & Stein, M. B. (2003; Friborg et al., 2013;
Sanderson et al. 1994).
Lastly, in this study mood disorders were associated with lower role functioning
for CHR- which is supported by previous research (Fulford et al. 2013). Specifically,
depression was significantly associated with impairment in role functioning. When
depression diagnoses was included in a regression analyses and negative symptoms were
controlled, depression was found to be a significant predictor of social functioning.
Therefore, additional studies need to be conducted to further evaluate the relationship
between depression, negative symptoms, and functioning.
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Course of Axis I and Axis II Disorders
Our study replicated findings from Lin et al. (2015), supporting that mood and
anxiety disorders are persistent and recurrent from baseline to follow-up in both CHR
subgroups. For CHR+ participants 48.3% of mood disorders and 34.5% of anxiety
disorders were persistent and recurrent. Among CHR-participants, 23.1% of mood
disorders and 46.2% of anxiety disorders were persistent. Our findings also conveyed that
personality disorders and attention-deficit and disruptive behavior disorders were also
persistent among the subgroups. It was also surprising that substance use rates were
rather low in this sample and was persistent in 15% of CHR- participants.
In assessing high risk individuals, it would be imperative to continue to screen for
psychiatric disorders in this population. We only had 42 individuals for these follow-up
analyses and were underpowered to perform additional analyses. Further studies may be
able to expand on this research and explore the impact the persistence of these disorders
may have on response to treatment and early intervention strategies. Also, additional
analyses may be able to make more meaningful interpretations about the course of
diagnoses in these subgroups.
Predictors of Conversion
Expectedly, positive symptoms were found to be a strong predictor of conversion
which is also consistent with previous studies. Yung et al. (2003) explored the duration of
attenuated positive symptoms in CHR individuals and results demonstrated that a longer
duration of these symptoms increased transition to psychosis. In another study, more
severe positive symptoms were found to be predictors of conversion (Carrion et al 2016).
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Although mood disorders were persistent in the RAP subgroups, it appears that
the presence of mood disorders predicts non-conversion to psychosis. Thus, having a
mood disorder appeared to be protective against psychosis, which likely indicates that
mood disorders account for the CHR presentation rather than being true risk factors for
psychosis. Further analyses on how mood disorders evolve during the other stages may
help to clarify the role of mood disorders in this population.
As mentioned previously, the RAP model has expanded to include CHR+ mod
and also the SLPs. In a more recent study, Carrión et al (2017) evaluated the course of
symptoms, differences in treatment outcomes, and conversion at different stages of the
model. In this paper, the RAP model has been updated to highlight the range in symptom
severity from moderate to severe for attenuated positive symptoms or the CHR+ stage.
The updated model is as follows CHR-  CHR+Mod  CHR+Sev SLP. CHR+Mod
has a total positive symptom score of <10 and for CHR+Sev a total positive symptom
score of ≥ 10. (For the purposes of this study, we are using the previous 3-stage model).
Results from this study indicate that risk for conversion is dependent on the entry point in
the model, with CHR- stage showing the lowest risk of conversion of 5.9% and the
highest symptom stability (70%). Whereas the SLP subgroup has the lowest symptom
stability and the highest conversion rate of 49%. For the CHR+ moderate and severe
subgroups, conversion rates were 28% and 11% respectively. The RAP staging model
suggests that interventions should be more specific to target symptom severity. With that
being said, individuals with more severe symptoms will be provided with more
aggressive treatment options. In this study, subjects in the CHR- and CHR+Mod
subgroups responded well to antidepressant medications, implying that antidepressants
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may be particularly effective in earlier stages. The differences in symptom presentation,
response to interventions, and conversion rates suggests that these subgroups are separate
entities and should not be clustered together when exploring targeted interventions. See
Figure 2. Additional studies could explore how disorders progress through these different
stages and also help to clarify whether or not high-risk individuals may be at a higher risk
of conversion compared to young adults who present with similar co-occurring disorders
without the high-risk status (Albert et al., 2018).
Strengths and Limitations
A major strength of this study was the long follow-up period which was
instrumental in assessing outcomes over a longer period of time. A limitation of this
study is the variability in follow-up times which revealed a smaller sample size and
smaller sample size included in follow-up analyses. We suggest additional analyses with
longer-term follow-up periods to hopefully replicate some of these findings and also
further explore the progression of psychiatric disorders in the RAP subgroups.
Conclusion
These findings provide implications for further research on the developmental
course of symptoms for high-risk individuals. The comorbid rates and persistence over
follow up of Axis I and Axis II disorders in the high-risk population suggests that there
needs to be further screening of these individuals. Findings revealed that functioning and
attenuated symptoms presentation vary in the subgroups. This research provides further
information on factors that can be used to create targeted interventions for individuals
who are in different stages of high-risk. Additionally, since affective, anxiety, behavioral
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concerns may be the impetus for seeking treatment, additional screening measures may
help to explore developmental pathways that may impact the course of psychosis.
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FIGURES
Figure 1. Recognition and Prevention (RAP) neurodevelopmental model (Repinted from
Cornblatt et al., 2003)
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Figure 2. Recognition and Prevention (RAP) model of progression of high-risk
symptoms (Modified from Lencz et al., 2004).
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